



June 2014

Drug Information Update

DRUG INFORMATION UPDATE

Table of Contents

NEW GENERICS TO MARKET	2
NEW DRUG ENTITIES.....	3
NEW INDICATIONS (EXISTING DRUGS)	4
FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS.....	5
STUDIES.....	8
RECALLS.....	19
CURRENT DRUG SHORTAGES.....	27
NEW DRUGS COMING TO MARKET	87

NEW GENERICS TO MARKET

GENERIC DRUG NAME	STRENGTH & DOSAGE FORM	GENERIC MANUFACTURER	BRAND NAME	APPROVAL DATE
Triamcinolone Acetonide	40 mg/mL vial	Raway Pharm.	Kenalog-40	07/23/09
Triamcinolone Acetonide	10 mg/mL vial	Sandoz	Kenalog-10	0723/09
Hydromorphone HCl ER	12 mg ER 24H tab	Actavis Pharma	Exalgo	05/27/14
Hydromorphone HCl ER	32 mg ER 24H tab	Mallinckrodt Ph	Exalgo	05/19/14
Hydromorphone HCl ER	8 mg ER 24H tab	Mallinckrodt Ph	Exalgo	05/19/14
Hydromorphone HCl ER	16 mg ER 24H tab	Mallinckrodt Ph	Exalgo	05/19/14

NEW DRUG ENTITIES

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
PRENATAL VITAMIN PREPARATIONS	VITAMEDMD REDICHEW RX	PRENATAL COMB NO.42/FOLIC ACID	1.4 MG	New Combination
INTEGRIN RECEPTOR ANTAGONIST, MONOCLONAL ANTIBODY	ENTYVIO	VEDOLIZUMAB	300 MG	New Entity
HEMORRHOIDAL PREP, ANTI-INFLAM STEROID/LOCAL ANESTH	HYDROCORTISONE- LIDOCAINE	HYDROCORT/LIDOCAINE IN COLEUS	2%-2%-1%	New Combination
ANTIHISTAMINES- 1 ST GENERATION	KARBINAL ER	CARBINOXAMINE MALEATE	4 MG/5 L	New Dosage Form
PRENATAL VITAMIN PREPARATIONS	VITAFOL NANO	PRENATAL NO.75/IRON/FOLATE #1	18 MG-1 MG	New Combination

NEW INDICATIONS (EXISTING DRUGS)

Aloxi®

May 29, 2014

ANTIEMETIC AGENT, APPROVED FOR CHILDREN BY THE U.S. FDA
U.S. MARKET EXCLUSIVITY EXTENDED BY SIX MONTHS TO OCTOBER 13, 2015

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruno Naito, "Eisai") announced today that the antiemetic agent Aloxi® (generic name: palonosetron HCl) has been approved in the U.S. for an additional indication regarding the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to up to 17 years by the U.S. Food and Drug Administration (FDA). Despite peak cancer incidence among children occurring within the first year of life, this is the first product for chemotherapy-induced nausea and vomiting (CINV) prevention approved in patients aged between 1 and 6 months after birth. Eisai's U.S. subsidiary Eisai Inc. markets this product based on having received exclusive marketing rights from Helsinn Healthcare S.A. (Headquarters: Lugano, Switzerland) for the U.S.

Article link:<http://www.eisai.com/news/news201428.html>

Source website:<http://www.eisai.com/>

Vectibix®

May 23, 2014

FDA Approves First-Line Use of Vectibix®(Panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., May 23, 2014/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Vectibix® (panitumumab) for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC). With this approval, Vectibix becomes the first and only biologic to offer a significant survival benefit as a first-line treatment with FOLFOX, one of the most commonly used chemotherapy regimens in the first-line setting for patients with wild-type KRAS mCRC. In addition, this approval converts the accelerated monotherapy approval to a full approval for Vectibix. FDA also approved the theascreen® KRAS RGQ PCR Kit developed by QIAGEN (therascreen KRAS test) as a companion diagnostic for Vectibix

Article link: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1934128

Source website:<http://www.amgen.com/>

FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS

Soliris (eculizumab) Concentrated Solution for IV Infusion by Alexion: Recall-Visible Particulates

[Posted 06/02/2014]

ISSUE: Alexion Pharmaceuticals, Inc. announced that it is initiating a voluntary recall of certain lots of Soliris (eculizumab) 300mg/30 mL concentrated solution for intravenous infusion. The administration of particulate, if present in a parenteral drug, poses a potential safety risk to patients in two general areas: immune reaction and blood clots. Particulates could cause blockage of flow of blood in vessels, which could be life-threatening. The single affected Soliris lot is #10007A. Although these lots currently remain in specification, Alexion is including the following remaining lots, which were produced with the same process component during vial filling, within the scope of the U.S. recall: 10002-1, 00006-1, 10003A, 10004A, 10005A, 10005AR, 10006A and 10008A.

BACKGROUND: Soliris is approved as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two ultra-rare and life-threatening disorders. Alexion and its distributors typically ship Soliris to healthcare providers in small quantities, which are timed to individual patient infusions, with the product being consumed before more is shipped. As product from the identified lots was last shipped on October 30, 2013, there is anticipated to be little, if any, material from these lots still remaining in commercial distribution.

RECOMMENDATION: Any person in possession of vials of Soliris from these lots should stop use and arrange for return of the product to Alexion immediately by calling 1-888-SOLIRIS (888-765-4747), Monday-Friday from 8:30am to 5:00pm Eastern Time (ET). Alexion is notifying its distributors and customers by letter being sent via Federal Express and is arranging for replacement of all recalled products.

Healthcare professionals and pharmacists with questions regarding this recall can contact Alexion at 1-888-765-4747, Monday-Friday from 8:30am to 5:00pm ET. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Unaffected lot numbers can continue to be used according to the instructions for use.

Article link:<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm399536.htm>

Source website:<http://www.fda.gov/>

Eszopiclone Containing Sleep Aids: Drug Safety Communication – Can Cause Next-Day Impairment

[Posted 05/15/2014]

ISSUE: FDA has notified health professionals and their medical care organizations of a new warning that the insomnia drug Lunesta (eszopiclone) can cause next-day impairment of driving and other activities that require alertness. FDA recommends a decreased starting dose of Lunesta to 1 mg at bedtime. Women and men are equally susceptible to impairment from Lunesta, so the recommended starting dose of 1 mg is the same for both. FDA approved changes to the Lunesta prescribing information and the patient Medication Guide to include these new recommendations. The drug labels for generic eszopiclone products will also be updated to include these changes.

BACKGROUND: A study of Lunesta found that the previously recommended dose of 3 mg can cause impairment to driving skills, memory, and coordination that can last more than 11 hours after receiving an evening dose (see Data Summary). Despite these driving and other problems, patients were often unaware they were impaired. The new lower recommended starting dose of 1 mg at bedtime will result in less drug in the blood the next day.

RECOMMENDATION: Health care professionals should follow the new dosing recommendations when starting patients on Lunesta. Patients should continue taking their prescribed dose of Lunesta and contact their health care professionals to ask about the most appropriate dose for them. FDA is continuing to evaluate the risk of impaired mental alertness with the entire class of sleep aid drugs, including over-the-counter drugs available without a prescription, and will update the public as new information becomes available.

Article link:<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm397536.htm>

Source website:<http://www.fda.gov/>

Pradaxa (dabigatran): Drug Safety Communication – Lower Risk for Stroke and Death, but Higher Risk for GI Bleeding Compared to Warfarin

[Posted 05/13/2014]

ISSUE: The FDA recently completed a new study in Medicare patients comparing Pradaxa to warfarin, for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death. The new study included information from more than 134,000 Medicare patients, 65 years or older, and found that among new users of blood-thinning drugs, Pradaxa was associated with a lower risk of clot related strokes, bleeding in the brain, and death, than warfarin. The study also found an increased risk of major gastrointestinal bleeding with use of Pradaxa as compared to

warfarin. The MI risk was similar for the two drugs. Importantly, the new study is based on a much larger and older patient population than those used in FDA's earlier review of post-market data, and employed a more sophisticated analytical method to capture and analyze the events of concern. This study's findings, except with regard to MI, are consistent with the clinical trial results that provided the basis for Pradaxa's approval. As a result of these latest findings, the FDA still considers Pradaxa to have a favorable benefit to risk profile and have made no changes to the current label or recommendations for use.

BACKGROUND: Pradaxa and warfarin are used to reduce the risk of stroke and blood clots in patients with a common type of abnormal heart rhythm called non-valvular atrial fibrillation (AF).

RECOMMENDATION: Patients should not stop taking Pradaxa (or warfarin) without first talking with their health care professionals. Stopping the use of blood-thinning medications such as Pradaxa and warfarin can increase the risk of stroke and lead to permanent disability and death. Health care professionals who prescribe Pradaxa should continue to follow the dosing recommendations in the drug label.

Article link:<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm397179.htm>

Source website:<http://www.fda.gov/>

STUDIES and RECENT TOPICS

Viagra Frisky Might Be Melanoma Risky

June 3, 2014

Men who used the erectile-function drug sildenafil (Viagra) had almost twice the risk of melanoma compared with men who never used the drug, a study of 26,000 men showed.

Article link:<http://www.medpagetoday.com/HematologyOncology/SkinCancer/46153>

Source website:<http://www.medpagetoday.com/>

Health Providers Slowly Embrace Drug Truvada to prevent HIV

June 3, 2014

When Adam Zeboski started using the HIV drug Truvada in November 2012, he was HIVfree himself, but in a relationship with a man who had been infected. He was taking one Truvada pill a day for prevention, or PrEP - the breezy term for preexposure prophylaxis. Multiple international studies had shown that daily use of Truvada could nearly eliminate the risk of contracting HIV.

Article link:<http://www.sfgate.com/health/article/Health-providers-slowly-embrace-drug-Truvada-to-5526316.php>

Source website:<http://www.sfgate.com/>

Antibiotic Lowers Death Risk for Elderly Patients With Pneumonia: Study

June 3, 2014

The antibiotic Zithromax (azithromycin) significantly lowers older pneumonia patients' risk of death but slightly increases their risk of heart attack, a new study indicates.

Article link:<http://consumer.healthday.com/senior-citizen-information-31/misc-aging-news-10/antibiotic-lowers-death-risk-for-elderly-patients-with-pneumonia-study-688356.html>

Source website:<http://consumer.healthday.com/>

Dalfampridine: Not Just a Walking Aid

June 2, 2014

Extended-release dalfampridine (Ampyra) is approved for boosting walking speed in multiple sclerosis patients, but its benefits extend to other aspects of physical function, according to a small study reported here.

Article link:<http://www.medpagetoday.com/MeetingCoverage/CMSC-ACRIMS/46114>

Source website:<http://www.medpagetoday.com/>

In Treating Some Cancer Patients, less is more: U.S. Studies

May 30, 2014

Doctors can scale back treatment for certain cancer patients, based on evidence that some drugs can be used less frequently, according to new information that is clearing the way for physicians to limit the risks of care.

Article link:<http://www.reuters.com/article/2014/05/30/health-cancer-treatmentidUSL1N0OG17S20140530?type=companyNews&feedType=RSS>

Source website:<http://www.reuters.com/>

Two Drugs Are Better Than One for Asthma Control: Study

May 29, 2014

People with asthma are likely to benefit from combining medications to manage their symptoms, a strategy that requires doctors and patients to work together to tweak prescriptions, Dutch researchers say.

Article link:<http://www.reuters.com/article/2014/05/29/us-asthma-treatment-reviewidUSKBN0E927620140529>

Source website:<http://www.reuters.com/>

Pfizer Psoriasis Drug Succeeds in Late-stage Trial

May 23, 2014

Pfizer Inc said its experimental psoriasis drug was effective in treating the condition in a late-stage trial.

Two doses of the drug, tofacitinib, maintained the treatment effect in patients suffering from moderate-to-severe chronic plaque psoriasis, the company said.

Article link:<http://www.reuters.com/article/2014/05/23/us-pfizer-study-psoriasisidUSKBN0E31AQ20140523>

Source website:<http://www.reuters.com/>

Researchers Explore New Target for Malaria Vaccine

May 22, 2014

Scientists have developed a new vaccine for malaria using protective immune system cells from children who appear to be naturally resistant to the deadly infectious disease. Initial tests of the vaccine in mice looked promising, according to a new study.

Article link:<http://consumer.healthday.com/infectious-disease-information-21/miscinfections->

news-411/researchers-find-new-malaria-vaccine-target-688089.html

Source website:<http://consumer.healthday.com/>

Alprazolam Misuse Still Sending Tens of Thousands to Emergency Rooms

May 22, 2014

Misuse of the popular sedative alprazolam, known by the trade name Xanax, sent more than 123,000 people to the emergency room in 2011, slightly fewer than the year before but more than double the number who went to the emergency room in 2005, a new report shows.

Article link:<http://www.usatoday.com/story/news/nation/2014/05/21/xanax-sends-people-to-emergency-room/9391719/>

Source website:<http://www.usatoday.com/>

Way too many doctors are prescribing antibiotics in error, study says

May 20, 2014

About 7 in 10 patients who go to a doctor seeking treatment for acute bronchitis winds up leaving their appointment with a prescription for an antibiotic, according to a new study in the Journal of the American Medical Assn. That's a problem, the study authors say, because the ideal prescription rate should be 0%.

Article link:<http://www.latimes.com/science/sciencenow/la-sci-sn-antibiotics-overuse-acutebronchitis-20140520-story.html>

Source website:<http://www.latimes.com/>

Novel Biologic Promising for Allergic Asthma

May 20, 2014

A novel first-in-class biologic agent targeting allergic inflammation appeared promising for allergen-induced asthma in a phase Ib trial. AMG 157, an anti-thymic stromal lymphopoietin (TSLP) humanized monoclonal antibody, reduced most measures of early and late asthmatic responses in response to allergen challenge, Paul M. O'Byrne, MB, of McMaster University in Hamilton, Ontario, and colleagues found.

Article link:<http://www.medpagetoday.com/MeetingCoverage/ATS/45887>

Source website:<http://www.medpagetoday.com/>

Myeloma Treatment Elotuzumab Receives Breakthrough Designation

May 19, 2014

The FDA has granted breakthrough designation to Bristol-Myers Squibb's experimental drug elotuzumab, to be used as part of a combo therapy with lenalidomide and dexamethasone for

the treatment of multiple myeloma in patients who have received one or more previous therapies, the firm said. The company is partnering with Abbott spinoff AbbVie on the drug, which currently is in phase III trials.

Article link:<http://www.fdanews.com/articles/164584-myeloma-treatment-elotuzumabreceives-breakthrough-designation>

Source website:<http://www.fdanews.com/>

Study Questions Role of Vitamin D in Asthma

May 19, 2014

Giving people with asthma and low vitamin D levels extra doses of the vitamin doesn't do much to help their lungs, a new study suggests. Previous research had linked low vitamin D levels to more asthma-related problems, like weaker lungs and more asthma exacerbations.

Article link:<http://www.reuters.com/article/2014/05/19/us-asthma-vitamin-didUSKBN0DZ1UG20140519?feedType=RSS&feedName=healthNews>

Source website:<http://www.reuters.com/>

Pancreatic Cancer May Become Number Two Cause of Cancer Deaths

May 20, 2014

Pancreatic cancer is projected to become the second most common cause of cancer-related death in the United States in 2030, overtaking deaths from breast and colon cancers, according to new research. Currently, the top three causes of cancer-related death in the United States are lung, colorectal and breast cancers. Pancreatic cancer is fourth, followed by prostate and liver cancers. In 2030, lung cancer will remain the top killer, but pancreatic cancer will move to second, followed by liver cancer and colorectal cancer, according to the report from the Pancreatic Cancer Action Network (PCAN), a charity organization that advocates for pancreatic cancer research.

Article link:<http://www.foxnews.com/health/2014/05/20/pancreatic-cancer-may-become-no-2-cause-cancer-deaths/>

Source website:<http://www.foxnews.com/>

Lung Treatments Slow Damage From Fatal Lung Disease in Studies

May 18, 2014

Drugs made by Intermune Inc. and Boehringer Ingelheim GmbH slowed progression of a lung disease with no cure that often kills people three to five years after diagnosis, according to findings reported by two studies.

Article link:<http://www.bloomberg.com/news/2014-05-19/lung-treatments-slow-damage-from-fatal-lung-disease-in-studies.html>

Source website:<http://www.bloomberg.com/>

Statins Flop in Sepsis and COPD

May 18, 2014

Statins don't prevent chronic obstructive pulmonary disease exacerbations or improve outcomes in sepsis-related respiratory failure, a series of trials showed. For patients with acute respiratory distress syndrome (ARDS) from sepsis in the ICU, rosuvastatin (Crestor) didn't cut 60-day in-hospital mortality compared with placebo (28.5% versus 24.9%, P=0.21) or boost ventilator-free days (mean 15.1 in both groups, P=0.96).

Article link:<http://www.medpagetoday.com/MeetingCoverage/ATS/45826>

Source website:<http://www.medpagetoday.com/>

Massive Dose of Measles Vaccine Clears Woman's Cancer

May 15, 2014

Mayo Clinic researchers announced a landmark study where a massive dose of the measles vaccine, enough to inoculate 10 million people, wiped out a Minnesota woman's incurable blood cancer.

Article link:<http://www.usatoday.com/story/news/nation-now/2014/05/15/measles-vaccinecancer-mayo-clinic/9115363/>

Source website:<http://www.usatoday.com/>

Some Prostate Cancer Patients Might Safely Delay Hormonal Therapy: Study

May 14, 2013

Hormone-depletion therapy is a common treatment for prostate cancer, but one that also carries side effects for men such as sexual dysfunction and fatigue. However, a new study suggests that in certain cases the treatment can be delayed --boosting the patient's quality of life.

Article link:<http://consumer.healthday.com/cancer-information-5/mis-cancer-news-102/some-prostate-cancer-patients-might-safely-delay-hormonal-therapy-study-suggests-687837.html>

Source website:<http://consumer.healthday.com/>

Prescription Drug Use Continues to Climb in the U.S.

May 14, 2014

Americans taking one or more medications. Among adults, the most common prescription drugs are for cardiovascular disease and high cholesterol.

Article link:<http://consumer.healthday.com/general-health-information-16/prescription-drugnews-551/prescription-drug-report-687822.html>

Source website:<http://consumer.healthday.com/>

Asthma Risk Up With Early Antibiotic Use

May 14, 2014

Kids treated with antibiotics before their first birthday have increased risk of asthma, researchers reported. And the risk increases the more often antibiotics are prescribed, according to Kenneth Mandl, MD, of Harvard Medical School, and colleagues.

Article link:<http://www.medpagetoday.com/Pediatrics/Asthma/45759>

Source website:<http://www.medpagetoday.com/>

Intensive Insulin Therapy Might Aid Diabetics After Heart Attack

May 13, 2014

Intensive insulin therapy may boost survival in people with type 2 diabetes who've suffered a heart attack, a new study suggests. Swedish researchers tracked outcomes for up to 20 years for 620 people with diabetes who were treated in hospital after a heart attack.

Article link:<http://consumer.healthday.com/diabetes-information-10/misc-diabetes-news-181/intensive-insulin-therapy-might-help-diabetics-who-ve-had-a-heart-attack-687733.html>

Source website:<http://consumer.healthday.com/>

Osteoporosis Drugs' Long-Term Use Needs More Research: FDA

May 13, 2014

The long-term risks and benefits of taking bisphosphonates, a class of drugs widely used for osteoporosis, require more research, according to the U.S. Food and Drug Administration. Bisphosphonates have been used in the United States since 1995 to treat people with osteoporosis, a condition in which bones become weak and are at increased risk of breaking. More than 44 million Americans are at risk for osteoporosis.

Article link:<http://consumer.healthday.com/caregiving-information-6/misc-therapy-andprocedures-health-news-658/osteoporosis-drugs-long-term-use-needs-more-research-fda->

687798.html

Source website:<http://consumer.healthday.com/>

FDA Study Offers Reassurance About Boehringer Ingelheim's Pradaxa

May 13, 2014

In the latest development in its ongoing review of the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim), the FDA today offered largely reassuring news about the sometimes controversial drug. The FDA study of 134,000 Medicare patients found that dabigatran was associated with a reduced risk for ischemic stroke, bleeding in the brain, and death, compared to warfarin. But the study also found that, dabigatran was associated with an increased risk for major gastrointestinal bleeding. There was no difference between the drugs in the risk of MI.

Article link:<http://www.forbes.com/sites/larryhusten/2014/05/13/fda-study-offersreassurance-about-boehringer-ingelheims-pradaxa/?ss=tech>

Source website:<http://www.forbes.com/>

Alcoholism Drugs Work in Study That May Dispel Doubts

May 14, 2014

Four medicines to treat alcoholism worked to reduce addiction, a study found, providing evidence that may overcome skepticism and spur greater use of the drugs. Naltrexone, a generic medicine, acamprosate, sold under the brand name Campral by Forest Laboratories Inc., Johnson & Johnson's seizure medicine Topamax and H. Lundbeck A/S's Selincro, helped alcoholics reduce their drinking, an analysis of more than 120 studies found. The oldest U.S.-approved alcoholism drug -- disulfiram, also known as Antabuse -- didn't prevent a return to drinking, according to research published in the Journal of the American Medical Association.

Article link:<http://www.bloomberg.com/news/2014-05-13/alcoholism-drugs-work-in-studythat-may-dispel-doubts.html>

Source website:<http://www.bloomberg.com/>

Red Wine Antioxidant Fails to Lengthen Lives in Study

May 13, 2014

Resveratrol, an ingredient in red wine thought to have health benefits, failed to promote longevity among Italians who ate a diet rich in the antioxidant, researchers said. A study of 783 men and women ages 65 and older found they didn't live longer and were just as likely to develop heart disease and cancer as those who consumed less resveratrol. The research, led by

Richard Semba, an ophthalmologist from Johns Hopkins University School of Medicine, followed the participants from two villages in Tuscany for nine years.

Article link:<http://www.bloomberg.com/news/2014-05-13/red-wine-antioxidant-fails-to-lengthen-lives-in-study.html>

Source website:<http://www.bloomberg.com/>

Lilly says Once-Daily Insulin Beats Sanofi's in Final Tests

May 12, 2014

Eli Lilly & Co. (LLY) said its experimental insulin helped diabetic patients more than Sanofi (SAN)'s biggest product in studies that also raised some safety risks. Lilly's once-a-day insulin injection was better than Sanofi's Lantus in controlling patients' blood sugar, a measure of how well a patients' diabetes is under control. Lilly, based in Indianapolis, said it will file for U.S. approval to sell the drug in the first quarter of next year.

Article link:<http://www.bloomberg.com/news/2014-05-12/lilly-says-its-once-daily-insulin-beats-sanofi-s-in-final-tests.html>

Source website:<http://www.bloomberg.com/>

GSK says heart drug darapladib fails in second late-stage trial

May 13, 2014

GlaxoSmithKline said its drug darapladib had not reduced heart attacks or other major events in patients with acute coronary syndrome, marking another disappointment for the innovative heart medicine.

Article link:<http://www.reuters.com/article/2014/05/13/us-glaxosmithkline-darapladibidUSKBN0DT0BU20140513>

Source website:<http://www.reuters.com/>

IL-17 Antibody Clears Psoriasis

May 12, 2014

Brodalumab, a monoclonal antibody that targets the interleukin (IL)-17 receptor, was effective in moderate-to-severe plaque psoriasis in a phase III study, Amgen and AstraZeneca announced. The trial's primary endpoint, a 75% improvement in the Psoriasis Area Severity Index (PASI 75) at week 12, was achieved by 83.3% of patients receiving a higher dose of brodalumab and by 60.3% of those given a lower dose, compared with 2.7% of patients on placebo.

Article link:<http://www.medpagetoday.com/Dermatology/Psoriasis/45737>

Source website:<http://www.medpagetoday.com/>

4 Drug Combinations That Can Be Accidentally Lethal

May 8, 2014

Nearly 28 percent of adults ages 20 to 59 hold multiple drug prescriptions at any given time, per Centers for Disease Control data. In some cases, double (or tripling) up is necessary— but the wrong combo could have critical consequences, says epidemiologist Leonard Paulozzi, M.D., M.P.H. Beware these potentially toxic matches, and always ask your doctor before mixing. And definitely check out our must-read article about accidental overdoses, a problem plaguing a scarily high number of women each year: The Silent and Growing Health Danger That All Women Need to Know About.

Article link:<http://time.com/93327/4-drug-combinations-that-can-be-accidentally-lethal/>

Source website:<http://time.com/>

Viagra, Cialis May Help Duchenne Muscular Dystrophy Patients

May 7, 2014

Drugs normally prescribed to treat erectile dysfunction in adult males may help boys who have a muscle disease called Duchenne muscular dystrophy, according to a new study.

Article link:<http://consumer.healthday.com/men-s-health-information-24/ cialis-news-814/viagra-cialis-may-help-boys-fight-muscular-dystrophy-687608.html>

Source website:<http://consumer.healthday.com/>

Medications May Reduce Violent Crime Risk in Those with Mental Illness

May 7, 2014

For people with severe psychiatric illness, taking an antipsychotic medication appears to drive down the risk of engaging in criminal violence, a large study has found. And for patients diagnosed with bipolar disorder, a mood-stabilizing medication has the same effect.

Article link:<http://www.latimes.com/science/la-sci-sn-medication-violent-crime-mentalillness-20140507-story.html>

Source website:<http://www.latimes.com/>

Thousands of Complaints on Blood-Pressure Drugs Spur Test

May 6, 2014

U.S. regulators plan an extensive study of blood-pressure drugs that generate almost 40 million prescriptions a year, after receiving thousands of complaints from doctors and patients.

Generics of AstraZeneca Plc (AZN)'s extended release Toprol XL make up about 90 percent of physicians' orders for the drug. The copycat drugs are made by Wockhardt Ltd. (WPL) and Dr. Reddy's Laboratories Ltd., both of which are based in India, and Mylan Inc. and Actavis Plc (ACT) in the U.S.

Article link:<http://www.bloomberg.com/news/2014-05-06/thousands-of-complaints-on-bloodpressure-drugs-spur-test.html>

Source website:<http://www.bloomberg.com/>

Stroke Rounds: Score Predicts Response to Clot Busters

May 6, 2014

Higher-risk patients according to a simple risk score incorporating age and stroke severity appear to derive the most benefit from thrombolytic therapy for an acute ischemic stroke, an observational study showed.

Article link:<http://www.medpagetoday.com/Cardiology/Strokes/45617>

Source website:<http://www.medpagetoday.com/>

Cheaper Copayments Boost Drug Follow-Up: Study

May 5, 2014

Nonwhite heart attack survivors are more likely to take prescribed medicines if their copayments are eliminated, according to a new study. Sticking with their drug treatment plan reduces these patients' risk for future heart problems and additional health care costs, the researchers noted.

Article link:<http://consumer.healthday.com/general-health-information-16/misc-drugs-news-218/copayments-heart-drugs-minorities-health-affairs-bwh-release-batch-1176-687491.html>

Source website:<http://consumer.healthday.com/>

Limit Use of Aspirin to Prevent Heart Attack, FDA Says

May 5, 2014

Aspirin generally shouldn't be used to prevent heart attacks or stroke for patients with no history of the disease, U.S. regulators said today. The use of the medicine raises serious risks of bleeding in the stomach and brain, the Food and Drug Administration said in a statement. While evidence shows that aspirin's benefits for people who have already had a cardiovascular event outweigh the increased risk of bleeding, the data doesn't support using the drug to help people prevent a first attack, the agency said.

Article link:<http://www.bloomberg.com/news/2014-05-05/limit-use-of-aspirin-to-preventheart-attack-fda-says.html>

Source website:<http://www.bloomberg.com/>

Gilead's Sovaldi Has Unclear Cancer Benefit, German Agency Says

May 2, 2014

Gilead Sciences Inc. (GILD)'s hepatitis C drug Sovaldi offers a benefit for patients, though the extent to which it prevents liver cancer is unclear, according to Germany's drug-review panel. While data submitted by Foster City, California-based Gilead showed Sovaldi can clear the virus, there was no proof that the drug helped prevent deaths, the Institute for Quality and Efficiency in Health, or IQWiG, said in a statement today.

Article link:<http://www.bloomberg.com/news/2014-05-02/gilead-s-sovaldi-has-unclearcancer-benefit-german-agency-says.html>

Source website:<http://www.bloomberg.com/>

RECALLS

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
Drugs	Effexor XR (venlafaxine HCl) Extended-Release Capsules, 150 mg, packaged in a) 30-count Unit of Use bottles (NDC 0008-0836-21) UPC 3 0008-0836-21 7; b) 90-count Unit of Use bottles (NDC 0008-0836-22) UPC 3 0008-0836-22 4; Rx only, Distributed by Wyeth Pharmaceuticals Inc., A subsidiary of Pfizer Inc., Philadelphia, PA 19101.	Lot #: a) V130142, Exp 10/15; b) V130140, Exp 10/15	Class I	Presence of Foreign Tablets/Capsules: A Pharmacist reported that a bottle of Effexor XR 150 mg capsules contained a single peach colored capsule printed TKN250 which was identified as a Tikosyn (dofetilide) capsule.	Pfizer Us Pharmaceutical Group
Drugs	Marcaïne (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045 USP, NDC 0409-1559-10.	Lot #: 34-440-DD, Exp 10/15	Class I	Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.	Hospira Inc.
Drugs	Venlafaxine HCl Extended-Release Capsules, 150 mg, 90-count Unit of Use bottles, Rx only, Distributed by: Greenstone LLC, Peapack, NJ 07977, NDC 59762-0182-2, UPC 3 59762-0182-2 9.	V130014, Exp 08/15	Class I	Presence of Foreign Tablets/Capsules: A Pharmacist reported a foreign capsule with markings (TKN 250) and identified as a Tikosyn (dofetilide) capsule in a lot of Effexor XR 150 mg capsules that was packaged in the same packaging campaign as this Venlafaxine HCl lot.	Greenstone Llc
Drugs	Midazolam 0.2 mg/2	Lot #:	Class I	Superpotent Drug:	Pharmakon

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	mL 0.9% Sodium Chloride syringes, Total dosage: 0.4 mg per 2 mL, Rx Only, Pharmakon Pharmaceuticals, Inc., 14450 Getz Rd, Noblesville, Indiana, NDC 45183-0014-69.	E1016227C, Exp. 4/21/2014; E0433735C, Exp. 4/20/2014		Product contains twice the stated amount of midazolam.	Pharmaceuticals
Drugs	CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-016.	Lot #: 280453F, Exp 04/16	Class I	Presence of Particulate Matter: Customer complaint stating that one vial contained a glass shard.	Cubist Pharmaceuticals, Inc.
Drugs	Dr. Reddy's Metoprolol Succinate Extended Release Tablets, USP 25 mg. 100-count bottle, Rx only, Manufactured By: Dr. Reddy's Laboratories Limited, Batchupally - 500 090 India. NDC55111-466-01	Lot # C206578 Exp. 05/14 Lot # C207415 Exp. 06/14	Class II	Failed Dissolution Specifications: Failure of dissolution test observed at the 18 month time point.	Dr. Reddy's Laboratories, Inc.
Drugs	Pantoprazole Sodium, Delayed-release tablets, USP, 40 mg tablets, 100 (10x10) unit dose packages, Manufactured by Dr. Reddy's Laboratories Limited, India and Distributed by Major Pharmaceuticals, Livonia, MI --- NDC 0904-6235-61	No lot or expiration date is displayed on this carton.	Class II	Correct Labeled Product Miscart/Mispack: some cartons labeled as Pantoprazole Sodium Delayed-Release may contain correctly labeled blister cards of Lorazepam tablets	Legacy Pharmaceutical Packaging
Drugs	INDOMETHACIN Capsules USP, 50 mg,	TE38139, Exp. 08/16, TE39022,	Class II	CGMP Deviations; laboratory testing	Teva Pharmaceutical

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	a) 100 count bottle, (NDC 0093-4030-01), b) 500 count bottle, (NDC 0093-4030-05), Manufactured In INDIA By: EMCURE PHARMACEUTICALS LTD pharmaceuticals Ltd., Hinjwadi, Pune, India, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960	Exp. 09/16,		was not followed in accordance with GMP requirements.	s USA
Drugs	phosLo (calcium acetate) GelCaps, 667 mg, 200-count bottle, Rx only, Manufactured for Fresenius Medical Care North America, Waltham, MA 02451, NDC 0781-2081-02	Lot # 13064, 13065, 13066; Exp. 08/18	Class II	Cross Contamination with Other Products: Potential for contaminant on the cotton packaging inside the bottle. Chemical analysis of the contaminant found on the cotton was identified as a formulation of 4% Trimipramine methanesulfonate - a tricyclic antidepressant..	Fresenius Medical Care Holdings, Inc.
Drugs	BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 2 mg, 30-count bottles, Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5378-56, UPC 3 0093-5378-56 5.	Lot #: 34013132A, 34013133A, 34013134A, 34013135A, 34013136A, Exp 11/14	Class II	Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.	Teva Pharmaceuticals USA
Drugs	BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 8 mg, 30-count bottles, Rx only, Teva	34009367B, 34009368B, 34009369A, 34009370B, Exp 04/14;	Class II	Failed Impurities/Degradation Specifications: High out of specification impurity	Teva Pharmaceuticals USA

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5379-56, UPC 3 0093-5379-56 2.	34013141A, 34013142A, Exp 11/14; 34016682A, 34016683A, 34016684A, 34017000A, 34017001A, Exp 08/15		test results were obtained during stability testing.	
Drugs	QVAR® (beclomethasone dipropionate HFA), 80mcg Inhalation Aerosol, 50 metered inhalations/120 metered inhalations, packaged in an aluminum cylinder, Mkted. by: Teva Respiratory, LLC, Horsham, PA, Mfd. by: 3M Drug Delivery Systems, Northridge, CA.	130140 11/2014 59310-204-85 80 mcg 4.2g / 50 metered inhalations 130143 3/2015 59310-204-80 80 mcg 8.7g / 120 metered inhalations 130144 3/2015 59310-204-80 80 mcg 8.7g / 120 metered inhalations	Class II	Defective Delivery System; defective valve	Teva Pharmaceuticals USA
Drugs	Liothyronine Sodium Tablets, USP 5 mcg, Rx Only, a) 100-count bottle NDC 42794-018-02 and b) 1000-count bottle NDC 42794-018-06, SigmaPharm Laboratories, LLC, Bensalem, Pa.	Lot #s: a) 1302201, Exp 01/2015; 1305501, Exp 03/2015; 1314801, Exp 10/2015; b) 1302202, Exp 01/2015	Class II	Cross Contamination with Other Products: Four lots of Liothyronine Sodium Tablets, USP 5 mcg are being recalled due to the finding of a potential carryover of trace amounts of a previously manufactured product.	SigmaPharm Laboratories LLC
Drugs	Bystolic (nebivolol), 20 mg/tablet, 30 tablets per bottle, Rx only, Licensed from Mylan Laboratories Inc., Under license from Janssen Pharmaceutica NV,	Lot: A287945, Exp: 08/2015	Class II	Failed Dissolution Specifications: One lot of product is being voluntarily recalled because dissolution test results failed to meet specification throughout the	Forest Pharmaceuticals Inc

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Belgium, Forest Pharmaceuticals, Inc., Subsidiary of Forest Laboratories, Inc., St. Louis, MO, NDC 0456-1420-30			product's shelf life.	
Drugs	PROMETHAZINE HYDROCHLORIDE Tablets, USP, 25 mg, 100 Tablet Bottles, Rx Only. Manufactured by: Cadila Healthcared Ltd., India. Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534. NDC: 68382-041-01	Lot #: MN9081, Expiry: 09/2015	Class II	Presence of Foreign Tablets: Presence of atenolol 25 mg tablet mixed into promethazine 25 mg tablet bottles.	Zydus Pharmaceuticals USA Inc
Drugs	ParaGard T 380A - Intrauterine Copper Contraceptive, 176 mg of copper wire, Duramed Pharmaceuticals Inc, a subsidiary of Barr Pharmaceuticals, Inc., Pomona, NY	508004, exp. 4/2015, NDC 51285-204-01, Single Unit 508004, exp. 4/2015, NDC 51285-204-02, Carton of 5 Units	Class II	Non-sterility: due to a failed sterility test	Teva Pharmaceuticals USA
Drugs	Cefpodoxime Proxetil Tablets, USP, 200 mg, 20 Tablet Bottles, Rx Only. Manufactured in Austria by Sandoz GmbH for Sandoz Inc. Princeton, NJ 08540. NDC 0781-5439-20.	Lot #: DZ4056, Expiry: 11/2015; Lot # DZ4057, Expiry: 01/2016	Class II	Presence of Particulate Matter: Presence of stainless steel particles.	Sandoz, Inc
Drugs	Metoprolol Succinate Extended-Release Tablets, USP, 100 mg, 100-count bottle, Rx only. Manufactured by: Wockhardt Limited, Mumbai, India; Distributed by: Wockhardt USA LLC.,	Lot #: LN11423, Expiry: 8/15/15	Class II	Failed Dissolution Specifications: Failure of dissolution test observed at three month time point.	Wockhardt Usa Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	20 Water view Blvd., Parsippany, NJ 07054, USA. NDC: 64679-736-02.				
Drugs	GREENSTONE BRAND fluconazole for Oral Suspension, ORANGE FLAVORED, 40 mg/mL, when reconstituted, Rx only, Distributed by Greenstone LLC Peapack, NJ 07977. MADE IN INDIA. NDC 59762-5030-1	Lot # A358502; Exp 01/15	Class II	Defective Container: Tamper evident ring failures discovered on some bottles.	Pfizer Inc.
Drugs	LOSARTAN POTASSIUM Tablets, USP, 50 mg, 30 count bottles, Rx only, Manufactured by Arrow Pharm (Malta) Ltd., Bizebbugia, Malta, Packaged by GSMS, Inc. Camarillo, CA --- NDC 60429-317-30	Lot Number GS003057. Exp Date 03/2016.	Class II	Presence of Foreign Substance; some bottles may contain debris that was swept up during cleaning	Golden State Medical Supply Inc.
Drugs	CareFusion Scrub Care Surgical Scrub Brush-Sponge/Nail Cleaner With 9% Povidone-iodine (USP) Surgical Hand Scrub; CareFusion, Vernon Hills, IL 60061 USA, NDC 57613-003-18	4451B; 4451GL	Class II	Subpotent Drug: CareFusion is recalling the CareFusion Scrub Care Surgical Scrub Brush-Sponge/Nail Cleaner. The available iodine in the product is less than as stated on the product label.	Carefusion 2200 Inc
Drugs	CareFusion Scrub Care Surgical Scrub Brush-Sponge/Nail Cleaner With 15% Povidone-iodine (USP) Surgical Hand Scrub; CareFusion, Vernon Hills, IL 60061 USA, NDC 57613-013-15.	4452B	Class II	Subpotent Drug: CareFusion is recalling the CareFusion Scrub Care Surgical Scrub Brush-Sponge/Nail Cleaner. The available iodine in the product is less than as stated	Carefusion 2200 Inc

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
				on the product label.	
Drugs	Oasis TEARS, Lubricant Eye Drops, 10mL/0.3 fl. oz. Bottle, OTC Only. Distributed by: OASIS, OASIS Medical, Inc., Glendora, CA 91741. UPC: 8 54819 00002 3.	Lot #: OTM-07, Expiry: 12/2015.	Class III	Labeling: Missing Label; The label on the immediate bottle is missing	Oasis Medical Inc
Drugs	PediaCare brand NIGHTTIME MULTI-SYMPTOM Cold, (diphenhydramine HCl 6.25 mg and phenylephrine HCl 2.5 mg), 4 FL OZ (118 mL), Distributed by Medtech Products, Inc., Tarrytown, NY ---- UPC 814832013544	UPC 814832013544 Lots: Expiry Date 133196 01/2015 144273 02/2015 154090 09/2015 73242 05/2014 73243 05/2014 73244 05/2014 73824 06/2014 74207 06/2014 74303 06/2014 74460 06/2014 78805 09/2014 79265 10/2014 79266 10/2014 79573 09/2014 80456 06/2014 80457 07/2014 83746 01/2015	Class III	Presence of Precipitate; small amounts of diphenhydramine precipitated out of solution	Prestige Brands Holdings
Drugs	PediaCare brand DAY & NIGHT Value Pack DAYTIME MULTI-SYMPTOM Cold (dextromethorphan HBr 5 mg and Phenylephrine HCl 2.5 mg) and NIGHTTIME MULTI-SYMPTOM Cold (diphenhydramine HCl 6.25 mg and phenylephrine HCl 2.5 mg), 4 FL oz (118 mL)	UPC 814832013523 Lots: Expiry Date 148342 07/2015 148347 08/2015 149297 08/2015 149382 07/2015 149516 08/2015 152298 08/2015 73143 04/2014 73719 05/2014 74195 06/2014 74805 06/2014 75180	Class III	Presence of Precipitate; small amounts of diphenhydramine precipitated out of solution	Prestige Brands Holdings

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	bottles, one each of DAYTIME MULTI- SYMPTOM Cold, Distributed by Medtech Products, Inc., Tarrytown, NY --- UPC 814832013523	06/2014 79186 09/2014 79323 09/2014			

CURRENT DRUG SHORTAGES

Dopamine Injection

May 22, 2014

Reason for the Shortage

- B Braun discontinued their dopamine premix in November 2012 due to raw material supply issues.
- Hospira states the shortage is due to manufacturing delays.
- American Regent has recently upgraded their manufacturing plant. Product will become available in stages as production resumes.
- Baxter has dopamine on allocation due to increased demand.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=88>

Source link: <http://www.ashp.org>

Neostigmine Methysulfate Injection

May 22, 2014

Reason for the Shortage

- Fresenius Kabi, USA (formerly APP) said the reason for the shortage is increased demand for the product.¹
- American Regent had temporarily suspended manufacture of most drug products in April, 2011.²
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011, but some products are still affected.
- West-Ward said the reason for the shortage was increased demand for the product.³

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=311>

Source link: <http://www.ashp.org>

Dextrose 5% Injection Large Volume Bags

May 22, 2014

Reason for the Shortage

- Baxter states the shortage is due to increased demand

- BBraun had 5% dextrose on allocation due to increased demand
- Hospira states the shortage is due to increased demand and manufacturing delays

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1081>

Source link: <http://www.ashp.org>

Cytarabine Injection

May 22, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) has cytarabine on shortage due to increased demand
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that have already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure
- Mylan Institutional acquired cytarabine injection from Pfizer on December 6, 2013

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=413>

Source link: <http://www.ashp.org>

Adenosine Injection

May 22, 2014

Reason for the Shortage

- Akorn launched adenosine 3 mg/mL 2 mL vials 25 count in April 2013.
- Astellas had Adenoscan on back order due to increased demand. This back order is now resolved. Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Sagent has adenosine syringes on shortage because the company is transferring suppliers of raw materials. The current supplier has exited the market.
- Teva has discontinued their adenosine injection.

- Wockhardt discontinued their adenosine 3 mg/mL 2 mL and 4 mL syringes.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=976>

Source link: <http://www.ashp.org>

Liotrix Tablets

May 23, 2014

Reason for the Shortage

- Thyrolar tablets from Forest Laboratories are on back order due to manufacturing changes

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=24>

Source link: <http://www.ashp.org>

Indigo Carmine Injection

May 23, 2014

Reason for the Shortage

- American Regent had temporarily suspended manufacture of most drug products in April, 2011.¹
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.¹
- Akorn has discontinued production of indigo carmine due to shortage of raw material. Akorn is looking for a new raw material supplier.²

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=861>

Source link: <http://www.ashp.org>

Doxapram Injection

May 23, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- West-Ward had Dopram on shortage due to manufacturing delays.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=877>
Source link: <http://www.ashp.org>

Succinylcholine chloride Injection

May 27, 2014

Reason for the Shortage

- Hospira had Quelicin on shortage due to manufacturing delays
- Sandoz had Anectine on shortage due to extra quality reviews.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=582>
Source link: <http://www.ashp.org>

Sodium Phosphate Injection

May 27, 2014

Reason for the Shortage

- American Regent has sodium phosphate injection on back order due to manufacturing delays.1,2
- American Regent has issued a statement that all lots of sodium phosphate have potential for crystallization. Do not use if any particles are present.3,4
- Hospira has sodium phosphate injection on shortage due to manufacturing delays.5
- In cooperation with FDA, Fresenius Kabi USA is providing Glycophos (sodium glycerophosphate) injection to the US market to help alleviate the shortage. Glycophos is manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG.6
- Fresenius Kabi launched sodium phosphate injection in mid-January 2014.7

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=7702>

Source link: <http://www.ashp.org>

Sincalide Injection

May 27, 2014

Reason for the Shortage

- Bracco Diagnostics has Kinevac on shortage due to manufacturing delays.
- There are no approved alternatives to Kinevac for the labeled indications.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1032>

Source link: <http://www.ashp.org>

Doxorubicin Injection

May 27, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Teva had doxorubicin on shortage due to manufacturing issues.
- Pfizer had doxorubicin solution for injection on shortage due to shipping delays.
- Sagent introduced doxorubicin injection in November 2013.
- Mylan Institutional acquired doxorubicin lyophilized powder from Pfizer on December 6, 2013.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=464>

Source link: <http://www.ashp.org>

Dextran Low Molecular Weight (Dextran 40) 10% Injection

May 27, 2014

Reason for the Shortage

- Hospira states the reason for the shortage is manufacturing delay.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1108>

Source link: <http://www.ashp.org>

Bumetanide Injection

May 27, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Baxter discontinued bumetanide 0.25 mg/mL 2 mL vial in early-2011.
- West-Ward acquired several Baxter products including bumetanide in mid-2011. Bumetanide was on shortage because demand exceeded supply.
- Hospira has bumetanide on shortage due to manufacturing delays.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=674>

Source link: <http://www.ashp.org>

Phenylephrine 2.5% and 10% Ophthalmic Solution

May 28, 2014

Reason for the Shortage

- Akorn stopped manufacturing their phenylephrine ophthalmic solution in April 2014 and the company will no longer distribute after June 30, 2014.
- Alcon discontinued phenylephrine 2.5% ophthalmic solution with the Sandoz label in April 2014.
- Alcon could not provide a reason for the shortage of Mydrin 2.5% ophthalmic solution. Mydrin is an unapproved product.
- Hub discontinued phenylephrine 2.5% and 10% ophthalmic solution in 2013.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1105>

Source link: <http://www.ashp.org>

Midazolam Injections

May 28, 2014

Reason for the Shortage

- West-Ward acquired Baxter's midazolam injection products in May, 2011.1
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that have already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.2
- Hospira has midazolam on shortage due to manufacturing delays and demand exceeding supply due to current market conditions.3
- Hospira discontinued midazolam 5 mg/mL 1 mL iSecure syringes in July 2011.3
- Fresenius Kabi (formerly APP) had midazolam on shortage due to increased demand.4
- Due to low demand, Akorn is focusing on other medications that are in greater need of supply.5
- FDA imposed an import ban in mid-2013 on several Wockhardt products including midazolam injection.8
- Medicines Company launched midazolam injection in early 2014.9

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=858>

Source link: <http://www.ashp.org>

Levocarnitine

May 28, 2014

Reason for the Shortage

- American Regent has levocarnitine injection on back order due to manufacturing delays.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Teva could not provide a reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=968>

Source link: <http://www.ashp.org>

Doxycycline Capsules and Tablets

May 28, 2014

Reason for the Shortage

- Actavis states the reason for the shortage is supply and demand.
- Teva discontinued their doxycycline presentations in May 2013.
- Major discontinued most doxycycline presentations in February 2013. The company could not provide a reason for the discontinuation.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=977>

Source link: <http://www.ashp.org>

Vitamin E Aqueous Oral Solution

May 29, 2014

Reason for the Shortage

- Hospira is changing manufacturing sites from a 3rd party manufacturer to in-house manufacturing. This has caused a delay in production

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=965>

Source link: <http://www.ashp.org>

Vinblastine Injection

May 29, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.¹
- Fresenius Kabi (formerly APP) had their product in short supply due to increased demand for the product and a manufacturing delay

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=883>

Source link: <http://www.ashp.org>

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

May 29, 2014

Reason for the Shortage

- Sanofi-Pasteur has Adacel is in short supply due to manufacturing delays. This product is also known as adult tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine.¹
- Sanofi-Pasteur is in the process of implementing new NDC numbers for vaccine products.¹
- GlaxoSmithKline has available Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Boostrix). The 1 count Boostrix syringe is no longer made.²
- Adult Tetanus and Diphtheria Toxoids Adsorbed (Td) (Tenivac, Sanofi-Pasteur) is not affected by this shortage.¹

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1051>

Source link: <http://www.ashp.org>

Tamoxifen Tablets

May 29, 2014

Reason for the Shortage

- Teva and Mylan could not provide a reason for the shortage.
- Actavis could not provide a reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1071>

Source link: <http://www.ashp.org>

Synthetic Conjugated Estrogen

May 29, 2014

Reason for the Shortage

- Teva could not provide a reason for the shortage.
- Premarin is not affected by this shortage

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1087>

Source link: <http://www.ashp.org>

Potassium Chloride Injection

May 29, 2014

Reason for the Shortage

- Hospira states the reason for the shortage is manufacturing delays.
- Fresenius Kabi and Baxter could not provide a reason for the shortage.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=696>

Source link: <http://www.ashp.org>

Famotidine Injection

May 29, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.¹
- West-Ward states the shortage is due to manufacturing delays.²
- Oral famotidine products are not affected by this shortage.
- Pfizer launched famotidine injections in March, 2012.³
- Mylan Institutional acquired famotidine injections from Pfizer on December 6, 2013.⁴

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=810>

Source link: <http://www.ashp.org>

Ciprofloxacin Injection

May 29, 2014

Reason for the Shortage

- Pfizer discontinued ciprofloxacin injection in 2010.
- Teva discontinued all ciprofloxacin injection in September, 2011.
- Bedford discontinued ciprofloxacin injection in May, 2011 to concentrate on the manufacturing of other products.

- Bayer took over Cipro IV from Merck in 2011.
- Claris, Hospira and Sagent could not provide a reason for the shortage.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=944>

Source link: <http://www.ashp.org>

Chlorprocaine Injection

May 29, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Hospira discontinued chlorprocaine injection in January, 2012 due to inability to obtain raw materials. All supply was depleted in January.
- Fresenius Kabi (formerly APP) has transitioned from 1 count presentations to 25 count sizes. All 1 count presentations were depleted in early 2012.
- Fresenius Kabi (formerly APP) had Nesacaine on shortage from depletion of raw materials due increased demand for the product

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=849>

Source link: <http://www.ashp.org>

Chloramphenicol Sodium Succinate Injection

May 29, 2014

Reason for the Shortage

- Fresenius Kabi has chloramphenicol injection on back order due to a raw material shortage.
- Fresenius Kabi is the sole supplier of chloramphenicol injection.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1068>

Source link: <http://www.ashp.org>

Aspirin Tablets (Buffered)

May 29, 2014

Reason for the Shortage

- Novartis has temporarily suspended manufacture of multiple drug products that were manufactured at the Lincoln facility including Bufferin and Ascriptin Tablets.
- Novartis voluntarily recalled all lots of Bufferin Tablets with expiration dates of December 20, 2013 or earlier.
- Novartis divested the rights for all Bufferin products to Ducere Pharma in early-2013.
- Ducere Pharma re-introduced Bufferin tablets in late 2013.
- Medique Products discontinued their buffered aspirin presentations in May, 2012.
- Major states the shortage was due to increased demand for the product.
- Teva discontinued their buffered aspirin products late 2009 and early 2010.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=950>

Source link: <http://www.ashp.org>

Ammonium Molybdate Injection

May 29, 2014

Reason for the Shortage

- American Regent has ammonium molybdate injection on shortage due to manufacturing delays.
- American Regent is the sole supplier of ammonium molybdate injection

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1003>

Source link: <http://www.ashp.org>

Alprostadil Products

May 29, 2014

Reason for the Shortage

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=968>

Source link: <http://www.ashp.org>

Levocarnitine

May 28, 2014

Reason for the Shortage

- Bedford discontinued alprostadil in May, 2011 to concentrate on the manufacturing of other products.
- Teva's product is on long-term back order due to manufacturing difficulties.²
- Pfizer's Caverject Impulse was on back order while the product was reformulated. The company has discontinued Caverject injection 10 mcg lyophilized powder and 20 mcg/mL solution for injection. Prostyn VR Pediatric was on back order for unknown reasons.³
- Actient has acquired several products from Schwarz (UCB) including Edex cartridges in 2010.^{4,5}
- Auxilium acquired Actient's urology products including Edex cartridges in April 2013.⁶
- Meda Pharmaceuticals has acquired Muse from Vivus

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=474>

Source link: <http://www.ashp.org>

Thiothixene Capsules

May 30, 2014

Reason for the Shortage

- Pfizer discontinued Navane (thiothixene) 2 mg, 10 mg, and 20 mg presentations in the fall of 2011. The Navane 5 mg presentation was discontinued previously.
- Sandoz discontinued all thiothixene presentations in early-2012.
- Mylan discontinued thiothixene 10 mg capsules in 1000 count in the first half of 2011 and discontinued thiothixene 2 mg and 5 mg capsules in 1000 count in early-April, 2012.
- Mylan cannot provide a reason for the shortage

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=835>

Source link: <http://www.ashp.org>

Sulfacetamide and Prednisolone Ophthalmic Ointment

May 30, 2014

Reason for the Shortage

- Allergan states the reason for shortage was difficulty in obtaining the raw materials needed for manufacturing.

- Allergan is the sole supplier of sulfacetamide 10% and prednisolone 0.2% ophthalmic ointment and ophthalmic suspension

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1033>

Source link: <http://www.ashp.org>

Sufentanil Injection

May 30, 2014

Reason for the Shortage

- West-Ward has sufentanil on shortage due to manufacturing delays
- Hospira has sufentanil on shortage due to manufacturing delays

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=823>

Source link: <http://www.ashp.org>

Prednisone Tablets

May 30, 2014

Reason for the Shortage

- Cadista states the shortage is due to a raw materials shortage.
- Perrigo discontinued prednisone tablets in 2013.
- Roxane and Watson could not provide a reason for the shortage.
- Qualitest discontinued prednisone 20 mg tablets in August 2013.
- West-Ward states the reason for the shortage was manufacturing delays

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=930>

Source link: <http://www.ashp.org>

Nicardipine Hydrochloride Injection

May 30, 2014

Reason for the Shortage

- Cornerstone Therapeutics discontinued Cardene ampules in March 2014. The company could not provide a reason for the discontinuation.
- Teva recalled 4 lots nicardipine injection because the product did not meet purity specifications. The recalled lots are 31302508B, 31302510B, 31302957B, 31303195B.

- Teva discontinued nicardipine injection in September, 2010.
- American Regent had temporarily suspended distribution of all drug products in April, 2011.
- American Regent resumed manufacturing in Shirely, New York in early-May, 2011.
- Mylan Institutional could not provide a reason for the shortage.
- Wockhardt has nicardipine on shortage due to an FDA import alert

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=31>

Source link: <http://www.ashp.org>

Milrinone Injection

May 30, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) states the reason for the shortage was increased demand for the product.
- West-Ward acquired Baxter's milrinone injection vials in May 2011.
- West-Ward states the shortage is due to manufacturing delays.
- Baxter had milrinone premixed bags on shortage due to increased demand.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Apotex, Bioniche, and Teva discontinued milrinone 1 mg/mL vials.
- Sanofi-Aventis discontinued Primacor injection

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=741>

Source link: <http://www.ashp.org>

Methylprednisolone Sodium Succinate Injection

May 30, 2014

Reason for the Shortage

- Hospira discontinued all methylprednisolone sodium succinate products in January 2013 due to raw material issues.¹
- Bedford discontinued methylprednisolone in May, 2011 to concentrate on the manufacturing of other products.²
- Pfizer has Solu-Medrol on shortage due to manufacturing delays.³

- Fresenius Kabi (formerly APP) has methylprednisolone sodium succinate on shortage due to priority of other medications

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1077>

Source link: <http://www.ashp.org>

Methotrexate Tablets

May 30, 2014

Reason for the Shortage

- Major discontinued methotrexate tablets in 2013.
- Mylan could not provide a reason for the shortage

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=961>

Source link: <http://www.ashp.org>

Methocarbamol Injection

May 30, 2014

Reason for the Shortage

- West-Ward states the reason for the shortage was due to manufacturing delays.
- There are no other manufacturers of methocarbamol injection.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=920>

Source link: <http://www.ashp.org>

Ketorolac Tromethamine Injection

May 30, 2014

Reason for the Shortage

- American Regent discontinued all ketorolac injection presentations in 2010.
- Fresenius Kabi (formerly APP) states the shortage was due to manufacturing delays.
- Baxter could not provide a reason for the shortage.
- Cura filed for bankruptcy in 2010.
- Hospira has ketorolac on shortage due to manufacturing delays for quality improvement activities and increased demand for the product.

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure. West-Ward has ketorolac injection on shortage due to manufacturing delays.
- West-Ward has ketorolac injection on shortage due to manufacturing delays

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=593>

Source link: <http://www.ashp.org>

Isosorbide Dinitrate Immediate Release Tablets

May 30, 2014

Reason for the Shortage

- Sandoz could not provide a reason for the shortage.
- Major discontinued isosorbide dinitrate 5 mg immediate release tablets in April 2012. Major discontinued isosorbide dinitrate 10 mg immediate release tablets in April 2013. Major discontinued isosorbide dinitrate 20 mg immediate release tablets in June 2013.
- West-Ward discontinued several isosorbide dinitrate immediate release tablet presentations in December 2013.
- West-Ward states the shortage is due to manufacturing delays

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=909>

Source link: <http://www.ashp.org>

Enalaprilat Injection

May 30, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Teva has discontinued both of their products.
- Hospira has enalaprilat injection on shortage due to manufacturing delays.
- West-Ward has enalaprilat injection on shortage due to manufacturing delays.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=587>

Source link: <http://www.ashp.org>

Dexmetomidine

May 30, 2014

Reason for the Shortage

- Hospira states the reason for the shortage is manufacturing delay.
- There are no other manufacturers of dexmedetomidine injection

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1092>

Source link: <http://www.ashp.org>

Cisplatin Injection

May 30, 2014

Reason for the Shortage

- Fresenius states the shortage was due to increased demand and manufacturing delays.1
- Mylan Institutional has cisplatin only available with short-dating.2
- Teva is allocating cisplatin to prevent stockpiling

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=57>

Source link: <http://www.ashp.org>

Piperacillin Tazobactam Injection

June 02, 2014

Reason for the Shortage

- Hospira has piperacillin/tazobactam on shortage due to manufacturing delays.
- Pfizer has Zosyn on shortage due to manufacturing delays

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1075>

Source link: <http://www.ashp.org>

Lorazepam Injectable Presentations

June 02, 2014

Reason for the Shortage

- Bedford discontinued lorazepam in May, 2011 to concentrate on the manufacturing of other products.¹
- West-Ward acquired Baxter's lorazepam injection products in May, 2011. NDC numbers for the lorazepam and Ativan products were changed in April, 2012.
- West-Ward has Ativan on back order due to increase surplus of the lorazepam presentations.²
- Hospira states lorazepam vials are on shortage due to increased demand and manufacturing delays. The 1 mL iSecure syringes were discontinued in September 2011.³
- Akorn has increased production to help meet demand.⁴
- Amphastar had lorazepam 2 mg/mL vials on shortage due to increased demand.⁵

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=747>

Source link: <http://www.ashp.org>

Ketamine Injection

June 02, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- JHP and Mylan Institutional could not provide a reason for the shortage.
- Hospira states the ketamine shortage is due to manufacturing delays

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=592>

Source link: <http://www.ashp.org>

Dexrazoxane Injection

June 02, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has

already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.

- Biocodex USA acquired Totect from Apricus Pharmaceuticals in April 2013.
- Apricus Pharmaceuticals acquired Topotarget USA in late 2011.
- Topotarget worked with FDA to extend the expiration date of specific batch numbers of Totect to 36 months. Information regarding this extension and the batch numbers can be found in four Dear Healthcare Customer letters available online.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=415>

Source link: <http://www.ashp.org>

Ascorbic Acid Injection

June 02, 2014

Reason for the Shortage

- American Regent had temporarily suspended distribution of most drug products in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.
- Hospira has discontinued all presentations of Cenolate injection and all supplies were depleted as of early-February, 2010.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=934>

Source link: <http://www.ashp.org>

Allopurinol Injection

June 02, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=998>

Source link: <http://www.ashp.org>

Norepinephrine Injection

June 03, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.¹
- Claris cannot provide a reason for the norepinephrine shortage.⁴
- Teva temporarily discontinued norepinephrine in June 2010.²
- Hospira has Levophed on shortage due manufacturing delays.₃

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=712>

Source link: <http://www.ashp.org>

Mecasermin Injection

June 03, 2014

Reason for the Shortage

- Ipsen Pharmaceuticals states the shortage is due to a manufacturing delay and raw material shortage.
- Ipsen is working with FDA to allow the release of Increlex lot #341203F. This lot was produced at an alternate manufacturing site that has not been approved by FDA. Please see the Dear Health Care Provider letter for additional information.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1058>

Source link: <http://www.ashp.org>

Desmopressin Injection

June 03, 2014

Reason for the Shortage

- Teva and Hospira have desmopressin injection on shortage due to manufacturing delays.
- Sanofi could not provide a reason for the shortage

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1010>

Source link: <http://www.ashp.org>

Denileukin Diftox Injection

June 03, 2014

Reason for the Shortage

- Eisai is working to resolve a manufacturing problem
- Eisai is the sole manufacturer of denileukin difitox

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1009>

Source link: <http://www.ashp.org>

Choline Magnesium Trisalicylate

June 03, 2014

Reason for the Shortage

- Caraco has discontinued their product. Product was recently seized by US Marshals due to good manufacturing practice violations (see news release for more information).
- Marlex could not provide a reason for their shortage

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=556>

Source link: <http://www.ashp.org>

Ceftazidime Injection

June 03, 2014

Reason for the Shortage

- Pfizer discontinued all of its ceftazidime injection products in late-November, 2011.
- West-Ward discontinued all of its ceftazidime injection products in January 2012.
- Hospira had ceftazidime on shortage due to manufacturing delays. Covis purchased all rights to Fortaz from GlaxoSmithKline. Covis began changing NDC numbers in December 2012.
- Sagent had ceftazidime injection on shortage due to increased demand for the product.
- WG Critical Care launched ceftazidime 1 gram vials in July 2013 and product is available at wholesalers. Ceftazidime 2 gram and 6 gram presentations were launched in August 2013

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=869>

Source link: <http://www.ashp.org>

Cefpodoxime

June 03, 2014

Reason for the Shortage

- Ranbaxy has an import ban on all solid medications including cefpodoxime.
- Aurobindo could not provide a reason for the shortage.
- Pfizer has discontinued Vantin.
- Sandoz could not provide a reason for the shortage

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=793>

Source link: <http://www.ashp.org>

Cefotetan Disodium Injection

June 03, 2014

Reason for the Shortage

- Fresenius Kabi states the reason for the shortage is manufacturing delay

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1097>

Source link: <http://www.ashp.org>

Black Widow Antivenin (Latrodectus Mactans)

June 03, 2014

Reason for the Shortage

- Merck has low inventory of Antivenin Latrodectus Mactans

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=670>

Source link: <http://www.ashp.org>

Tiopronin Tablets

June 04, 2014

Reason for the Shortage

- Mission Pharmacal has Thiola on shortage due to raw materials being discontinued

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1067>

Source link: <http://www.ashp.org>

Procainamide Hydrochloride Injection

June 04, 2014

Reason for the Shortage

- Hospira had procainamide injection on shortage due to manufacturing delays.
- There are no other manufacturers of procainamide injection

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=868>

Source link: <http://www.ashp.org>

Calcium Gluconate Injection

June 04, 2014

Reason for the Shortage

- American Regent has calcium gluconate on shortage due to manufacturing delays.

- Fresenius Kabi had calcium gluconate on shortage due to increase demand for the product.
- American Regent has issued a statement that all lots of calcium gluconate may contain glass particles and filters must be used. Do not use if there are visible glass particles and filter all other product

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=48>

Source link: <http://www.ashp.org>

Bumetanide Tablets

June 04, 2014

Reason for the Shortage

- Mylan Institutional discontinued bumetanide tablets in March 2014.
- Sandoz cannot provide a reason for the shortage.
- Teva cannot provide a reason for the shortage

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1073>

Source link: <http://www.ashp.org>

Vincristine Injection

June 05, 2014

Reason for the Shortage

- Hospira states the shortage is due to manufacturing delays
- Teva states vincristine injection is on allocation due to increased demand

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=42>

Source link: <http://www.ashp.org>

Vecuronium Bromide Injection

June 05, 2014

Reason for the Shortage

- Hospira states the shortage is due to manufacturing delays.
- Teva states the shortage is due to manufacturing delays.
- Pfizer sold vecuronium injection to Mylan Institutional in December 2013

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Sagent temporarily suspended the manufacture of vecuronium 10 mg and 20 mg vials.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=490>

Source link: <http://www.ashp.org>

Ticarcillin Clavulanate

June 05, 2014

Reason for the Shortage

- GlaxoSmithKline could not provide a reason for the shortage.
- GlaxoSmithKline discontinued Timentin 3.1 gram ADD-Vantage vials in late-2012.
- Baxter could not provide a reason for the shortage

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=802>

Source link: <http://www.ashp.org>

Sumatriptan Succinate Injection

June 05, 2014

Reason for the Shortage

- Sagent states the reason for the shortage is increased demand.
- JHP could not provide a reason for the shortage.
- GlaxoSmithKline could not provide a reason for the shortage.
- Pfizer has had Alsuma on shortage since September 2013 due to manufacturing issues.
- Teva has temporarily suspended the production of sumatriptan injection.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1085>

Source link: <http://www.ashp.org>

Rocuronium Injection

June 05, 2014

Reason for the Shortage

- Merck (formerly Schering-Plough) acquired Zemuron from Organon on July 1, 2008. The 5 mL vials were on back order at the time the company acquired the product.¹ Some generic products have had intermittent supply problems due to increased demand for product.²⁻⁷
- Merck (formerly Schering-Plough) discontinued Zemuron 10 mg/mL 10 mL multidose vials in the 3rd Quarter of 2013.¹
- Mylan Institutional (formerly Bioniche) acquired multiple products from Generamedix, including rocuronium. Mylan Institutional states the reason for the shortage was increased demand.^{2,3}
- Hospira has rocuronium on shortage due to manufacturing delays.⁴
- Teva has rocuronium on shortage due to manufacturing delays.⁵
- APP and Sagent cited increased demand as the reason for this shortage.^{6,8}
- The Medicines Company launched rocuronium in early 2014.⁹

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=434>

Source link: <http://www.ashp.org>

Reserpine Oral Tablets

June 05, 2014

Reason for the Shortage

- Sandoz said the shortage is due to a delay in obtaining raw materials.
- There are no other manufacturers of reserpine tablets.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=975>

Source link: <http://www.ashp.org>

Polymixin B Sulfate Injection

June 05, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) could not provide a reason for the shortage.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.¹
- Sagent suspended manufacturing of Polymyxin B sulfate injection in October, 2012.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=974>

Source link: <http://www.ashp.org>

Pantoprazole Tablets

June 05, 2014

Reason for the Shortage

- Actavis, Aurobindo, Mylan, Teva, and Torrent could not provide a reason for the shortage.
- Major and Kremers Urban state the shortage is due to increased demand.
- FDA imposed an import ban in mid-2013 on several Wockhardt products including pantoprazole.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=979>

Source link: <http://www.ashp.org>

Metronidazole Injection

June 05, 2014

Reason for the Shortage

- Hospira has metronidazole injection on back order due to manufacturing delays.
- Baxter, BBraun, and Claris are allocating metronidazole injection due to increased demand for the product

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=643>

Source link: <http://www.ashp.org>

Metoprolol Injection

June 05, 2014

Reason for the Shortage

- American Regent had temporarily suspended manufacture of most drug products including metoprolol in April, 2011.¹ The company Regent resumed manufacturing in Shirley, New York in early-May, 2011.²
- Fresenius Kabi (formerly APP) and Hospira state the shortage was due to increased demand for the product.^{3,4}
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford

Laboratories has a small number of products manufactured elsewhere that are not affected by this closure, metoprolol is not one of these medications.^{5,6}

- Sagent had metoprolol injection on shortage due to increased demand for the product.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=813>

Source link: <http://www.ashp.org>

Methylphenidate Hydrochloride

June 05, 2014

Reason for the Shortage

- Mallinckrodt states the shortage was due to delay in obtaining raw materials. The company has stopped using the trade name Methylin and all products are now marketed as methylphenidate immediate-release or extended-release tablets with new NDC numbers.
- Sandoz states that the shortage is due to delay in obtaining raw materials.
- Teva introduced generic methylphenidate extended release capsules (CD) in late-September 2012, and these capsules are AB-rated to Metadate CD capsules.
- UCB states methylphenidate IR tablets were on shortage due to supply and demand.
- Actavis (formerly Watson) says the methylphenidate IR tablets are on shortage due to supply constraints.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=752>

Source link: <http://www.ashp.org>

Methotrexate Injection

June 05, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that have already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure
- Sandoz recalled two lots of methotrexate 40 mL preservative-free vials in May 2013 due to discover of particulate matter during routine quality control inspection
- Mylan Institutional acquired methotrexate injection from Pfizer on December 6, 2013
- Mylan Institutional divested three presentations of methotrexate injection to Intas (Accord Healthcare) in April 2014

- Bioniche was acquired by Mylan Institutional in September, 2011
- Teva discontinued methotrexate 4 mL vials in October 2013 due to business reasons.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=26>

Source link: <http://www.ashp.org>

Methazolamide Tablets

June 05, 2014

Reason for the Shortage

- Sandoz cannot provide a reason for the shortage.
- Perrigo acquired Neptazane tablets and methazolamide tablets from Fera.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=901>

Source link: <http://www.ashp.org>

Bacitracin Topical Ointment

June 05, 2014

Reason for the Shortage

- Sandoz, Perrigo, and G&W Labs cannot provide a reason for the shortage

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=677>

Source link: <http://www.ashp.org>

Zinc Injection

June 06, 2014

Reason for the Shortage

- Hospira states the shortage of zinc chloride injection is due to manufacturing delays.
- Hospira is the only manufacturer of zinc chloride injection.
- American Regent had temporarily suspended manufacture of most drug products in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.
- FDA is allowing temporary importation of zinc gluconate trihydrate 1 mg/mL 10 mL vials from Aguettant Laboratories in France. This product is being distributed through Baxter Healthcare. The labeling will come in the original container which is in French. Information translated into English along with a table comparing the US and French products can be found in the Dear Healthcare Professional Letter

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=777>

Source link: <http://www.ashp.org>

Papaverine Injection

June 06, 2014

Reason for the Shortage

- Bedford and Sandoz have discontinued their papaverine presentations.^{1,2}
- American Regent, the sole supplier of papaverine injection, had temporarily suspended distribution of all drug products in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=781>

Source link: <http://www.ashp.org>

Magnesium Sulfate Injection

June 06, 2014

Reason for the Shortage

- American Regent had temporarily suspended distribution of most drug products including magnesium sulfate injection in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.
- Fresenius Kabi (formerly APP) had magnesium sulfate injection on shortage due to increased demand for the product.
- Hospira has magnesium sulfate injection on shortage due to manufacturing delays

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=757>

Source link: <http://www.ashp.org>

Labetalol Injection

June 06, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that have already been manufactured will continue to be released until inventory is depleted. Bedford

Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.

- Hospira has labetalol on shortage due to manufacturing delays and increased demand.
- Apotex discontinued their 4 mL vials (NDC 60505-0717-00) in February, 2010. The company could not provide a reason for the discontinuation.
- Sagent suspended production on labetalol 5 mg/mL 20 mL vials in July 2013.
- Sagent suspended production on labetalol 5 mg/mL 20 mL vials in July 2013 and 40 mL vials in February 2014.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=397>

Source link: <http://www.ashp.org>

Intravenous Fat Emulsion

June 06, 2014

Reason for the Shortage

- Hospira recalled several lots of Liposyn II and Liposyn III presentations.
- Hospira has discontinued the Liposyn II presentations because the raw material is unavailable.
- Hospira has Liposyn III on shortage due to manufacturing delays.
- Baxter had Intralipid presentations on intermittent back order due to increased demand.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=651>

Source link: <http://www.ashp.org>

Fosphenytoin Injection

June 06, 2014

Reason for the Shortage

- Akorn discontinued fosphenytoin injection in 2011.1
- Fresenius Kabi recalled numerous lots of fosphenytoin due to particulate matter potentially from glass delamination and consistent with glass particulates observed in samples. Fresenius Kabi has a letter discussing the lot numbers and what to do with affected product.2
- American Regent discontinued fosphenytoin injection in late-2010.3
- Bedford discontinued fosphenytoin in May, 2011 to concentrate on the manufacturing of other products.4
- Hospira states the shortage is due to manufacturing delays.5,6
- Pfizer discontinued the Cerebyx 500 mg presentation in September, 2009 and the 1 gram presentation in early-February, 2010.7

- Pfizer launched Cerebyx 2 mL and 10 mL vials in October 2013.7
- Teva, Apotex, Baxter, GeneraMedix, and Wockhardt have discontinued their fosphenytoin presentations.8-

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=127>

Source link: <http://www.ashp.org>

Ephedrine Injection

June 06, 2014

Reason for the Shortage

- Sandoz cannot provide a reason for the shortage
- Hospira discontinued ephedrine in March, 2011

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=351>

Source link: <http://www.ashp.org>

Calcitriol Injection

June 06, 2014

Reason for the Shortage

- Akorn has calcitriol injection on shortage due to increased demand for the product.
- American Regent has calcitriol on back order due to manufacturing delays.
- Abbott discontinued Calcijex in April 2012.
- West-Ward discontinued their calcitriol injection in May, 2011.
- Calcitriol capsule and oral solution presentations are available from multiple manufacturers.
- Fresenius Kabi (formerly APP) discontinued calcitriol injection in January 2014.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=940>

Source link: <http://www.ashp.org>

Acetylcysteine Inhalation Solution

June 06, 2014

Reason for the Shortage

- American Regent had temporarily suspended distribution of most drug products in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.

- Roxane Labs discontinued acetylcysteine inhalation solution in April 2014. The product had previously been on shortage due to manufacturing delays.
- Hospira has acetylcysteine inhalation solution on shortage due to manufacturing delay.
- Fresenius Kabi (formerly APP) states the reason for the shortage was increased demand.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=932>

Source link: <http://www.ashp.org>

Gentamicin Injection

June 09, 2014

Reason for the Shortage

- Hospira has gentamicin on shortage due to manufacturing delays¹
- Fresenius Kabi (formerly APP) had gentamicin on shortage due to increased demand. Fresenius Kabi discontinued their 10 mg/mL 2 mL multi-dose vial in mid-2011²
- Baxter has gentamicin on shortage due to increased demand.³

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=728>

Source link: <http://www.ashp.org>

Verapamil Injection

June 10, 2014

Reason for the Shortage

- Hospira states the shortage was due to manufacturing delays.
- Hospira is the sole supplier if verapamil injection.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=744>

Source link: <http://www.ashp.org>

Phenytoin Injection

June 10, 2014

Reason for the Shortage

- West-Ward has phenytoin on allocation due to increased demand.^{1,2}
- Hospira has phenytoin ampules on shortage due to increased demand for the product. Hospira discontinued phenytoin Carpuject syringes in August 2013 for business reasons.³

- X-Gen Pharmaceuticals had phenytoin on shortage due to manufacturing delays.⁴

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=740>

Source link: <http://www.ashp.org>

Dihydroergotamine Mesylate Injection

June 10, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Valeant cannot provide a reason for the shortage of dihydroergotamine mesylate injection.
- Paddock states the reason for the shortage is manufacturing delay.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1050>

Source link: <http://www.ashp.org>

Daunorubicin Hydrochloride Injection

June 10, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.¹
- Teva states daunorubicin was on back order due to manufacturing delays.²

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1007>

Source link: <http://www.ashp.org>

Dacarbazine Injection

June 10, 2014

Reason for the Shortage

- Teva had dacarbazine on back order due to manufacturing delays.¹
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=949>

Source link: <http://www.ashp.org>

Sodium Chloride Concentrated Solution for Injection

June 11, 2014

Reason for the Shortage

- American Regent discontinued 23.4% sodium chloride 30 mL and 100 mL presentations in 2012.
- Baxter discontinued their sodium chloride 250 mL presentation in 2008.
- Fresenius Kabi (formerly APP) has sodium chloride concentrated solution on shortage due to increased demand. Fresenius Kabi discontinued 14.6% sodium chloride 20 mL vials in February 2013.
- Hospira has 14.6% and 23.4% sodium chloride solutions for injection on shortage due to manufacturing delays. Hospira discontinued sodium chloride 14.6% solution 250 mL vials in February 2011.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=724>

Source link: <http://www.ashp.org>

Propranolol Injection

June 11, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Fresenius Kabi had propranolol injection available but with short-expiration dating.
- Sandoz cannot provide a reason for the shortage.

- West-Ward has propranolol injection on shortage due to manufacturing delays

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1091>

Source link: <http://www.ashp.org>

Potassium Phosphate Injection

June 11, 2014

Reason for the Shortage

- American Regent has potassium phosphate injection on back order due to manufacturing delays.^{1,2}
- American Regent has issued a statement that all lots of potassium phosphate may contain glass particles and filters must be used. Do not use if there are visible glass particles and filter all other product.^{3,4}
- Hospira has potassium phosphate 15 mL vials on shortage due to increased demand.⁵
- In cooperation with FDA, Fresenius Kabi USA is providing Glycophos (sodium glycerophosphate) injection to the US market to help alleviate the shortage. Glycophos is manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG.⁶
- Fresenius Kabi, USA (formerly APP) launched potassium phosphate injection in November 2013

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=709>

Source link: <http://www.ashp.org>

Naproxen Oral Suspension

June 11, 2014

Reason for the Shortage

- Roxane discontinued their naproxen oral suspension in June 2013.
- Genentech could not provide a reason for the shortage.
- Palmetto acquired naproxen 25 mg/mL oral suspension in June 2013

Article link

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1055>

Source link: <http://www.ashp.org>

Lidocaine with Epinephrine Injection

June 02, 2014

Reason for the Shortage

- Hospira has lidocaine with epinephrine presentations on shortage due to manufacturing delays.
- Fresenius Kabi (formerly APP) had Xylocaine with epinephrine presentations on shortage due to increased demand for the product.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=860>

Source link: <http://www.ashp.org>

Lactated Ringer's Injection Bags

June 11, 2014

Reason for the Shortage

- Baxter has lactated ringer's on shortage due to increased demand.1
- BBraun has lactated ringer's on allocation due to increased demand.2
- Hospira cites increased demand as the reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1078>

Source link: <http://www.ashp.org>

Fentanyl Injection

June 11, 2014

Reason for the Shortage

- West-Ward acquired Baxter's fentanyl injection products in May, 2011. The company began changing NDC numbers in July, 2012
- West-Ward states the shortage was due to a manufacturing delay for the fentanyl 50 mcg/mL 20 mL ampules. The 20 mL vials were in short supply due to increased demand
- Hospira states the shortage is due to increased demand and manufacturing delays including quality improvement activities. Hospira is increasing production of the ampules to help meet the demand
- Akorn launched Sublimaze injection in late-March, 2012

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=647>

Source link: <http://www.ashp.org>

Epinephrine Injection

June 11, 2014

Reason for the Shortage

- American Regent has epinephrine on shortage due to manufacturing delays.
- Hospira has epinephrine syringes on shortage due to manufacturing delays.
- JHP states the reason for the shortage was due to increased demand.
- JHP discontinued three epinephrine presentations in late-2013.
- Amphastar states the shortage was due to increased demand. Amphastar changed the NDC numbers of their epinephrine products in November 2012.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=685>

Source link: <http://www.ashp.org>

Bupivacaine with Epinephrine Injection

June 11, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) has Sensorcaine with epinephrine on shortage due to increased demand for the product.
- Hospira has bupivacaine with epinephrine and Marcaine with epinephrine on shortage due to manufacturing delays.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=937>

Source link: <http://www.ashp.org>

Benztropine Injection

June 11, 2014

Reason for the Shortage

- American Regent has benztropine injection on back order due to manufacturing delays.
- Fresenius Kabi USA recalled benztropine injection due to potential for glass particles in the vials. Product may have been under APP or Nexus labels. Detailed information on the recall can be found online.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1042>

Source link: <http://www.ashp.org>

Azithromycin Injection

June 11, 2014

Reason for the Shortage

- Fresenius Kabi could not provide a reason for the shortage.
- Hospira has azithromycin injection on shortage due to increased demand.
- Sagent has azithromycin injection on shortage due to increased demand.
- Pfizer discontinued Zithromax 500 mg vial with Vial-Mate Adaptor in January 2013.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=936>

Source link: <http://www.ashp.org>

Vancomycin Hydrochloride Injection

June 12, 2014

Reason for the Shortage

- Hospira has vancomycin on shortage due to increased demand
- Fresenius Kabi (formerly APP) has vancomycin injection on shortage due to increased demand.
- Sagent has vancomycin on shortage due to increased demand.
- Akorn has sold their vancomycin products to Pfizer and stopped distributing on April 29, 2011.
- Mylan Institutional acquired vancomycin injection from Pfizer on December 6, 2013.
- Mylan Institutional (formerly Bioniche) has acquired multiple products from Generamedix, including vancomycin hydrochloride.
- Mylan Institutional discontinued two vancomycin presentations in September 2013.
- Pfizer acquired multiple products from Akorn, including vancomycin hydrochloride in early-May, 2011

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=132>

Source link: <http://www.ashp.org>

Tobramycin Injection

June 12, 2014

Reason for the Shortage

- Teva has tobramycin solution for injection on shortage due to manufacturing delays.
- Hospira has tobramycin on shortage due to manufacturing delays.
- Pfizer acquired tobramycin injection from Akorn in early-May, 2011.
- Pfizer divested tobramycin injection to Mylan Institutional on December 6, 2013.

- Mylan Institutional could not provide a reason for the shortage

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=701>

Source link: <http://www.ashp.org>

Sodium Chloride 0.45% Injection Bags

June 12, 2014

Reason for the Shortage

- Baxter has 0.45% sodium chloride on shortage due to increased demand.
- BBraun had 0.45% sodium chloride on allocation due to increased demand.
- Hospira cited increased demand as the reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1083>

Source link: <http://www.ashp.org>

Rabies Immune Globulin

June 12, 2014

Reason for the Shortage

- Sanofi Pasteur states the reason for the shortage is increased demand and manufacturing delay.¹
- Grifols had HyperRab on back order due to increased demand

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=331>

Source link: <http://www.ashp.org>

Oxytocin Injection

June 12, 2014

Reason for the Shortage

- Fresenius Kabi, USA (formerly APP) states the shortage is due to increased demand.
- JHP could not provide a reason for the shortage.
- West-Ward states the shortage is due to stock becoming short-dated.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=876>

Source link: <http://www.ashp.org>

Morphine Injections

June 12, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) states the shortage is due to a change in manufacturing sites.
- Hospira states the shortage is due to manufacturing delays.
- Hospira discontinued preservative-containing Carpuject syringes in August, 2012 and replaced them with preservative-free Carpuject syringes.
- West-Ward states the shortage was due to increased demand for product. West-Ward changed old Baxter to new West-Ward NDC codes in early 2012.
- IMS (Amphastar) discontinued morphine 1 mg/mL 10 mL Luer-lock syringes in March, 2012 due to low demand for the product.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=664>

Source link: <http://www.ashp.org>

Mesna Injection

June 12, 2014

Reason for the Shortage

- Teva has a shortage of mesna injection due to manufacturing delays.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=642>

Source link: <http://www.ashp.org>

Lidocaine Injection

June 12, 2014

Reason for the Shortage

- Hospira has lidocaine presentations on shortage due to manufacturing delays.
- Fresenius Kabi, USA (formerly APP) has Xylocaine and lidocaine presentations on shortage due to increased demand for the product.

- Amphastar had lidocaine 2% emergency syringes on shortage due to increased demand for the product.
- BBraun has lidocaine and dextrose premixed bags on shortage due to increased demand for the product.
- Baxter discontinued two lidocaine and dextrose premixed bag presentations in March, 2012.
- AuroMedics introduced lidocaine injection in February 2014.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=859>

Source link: <http://www.ashp.org>

Isoniazide Tablets

June 12, 2014

Reason for the Shortage

- Versapharm could not provide a reason for the shortage.
- West-Ward discontinued isoniazid tablets in late-November 2013.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=985>

Source link: <http://www.ashp.org>

Indocyanine Green

June 12, 2014

Reason for the Shortage

- Akorn states the reason for the shortage is increased demand.
- Hub Pharmaceuticals cannot provide a reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1107>

Source link: <http://www.ashp.org>

Hydromorphone Hydrochloride Injection

June 12, 2014

Reason for the Shortage

- Hospira has hydromorphone injection on shortage due to manufacturing delays.
- West-Ward could not provide a reason for the shortage.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=856>

Source link: <http://www.ashp.org>

Haloperidol Lactate Injection

June 12, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Mylan Institutional could not provide a reason for the shortage.
- Sagent has haloperidol lactate on shortage due to manufacturing delays.
- Teva has haloperidol lactate on shortage due to manufacturing delays.
- Mylan Institutional acquired haloperidol lactate injection from Pfizer on December 6, 2013.
- Janssen and Patriot Pharmaceuticals state the reason for the shortage is increased demand.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=527>

Source link: <http://www.ashp.org>

Empty Evacuated Containers

June 12, 2014

Reason for the Shortage

- Hospira is changing the type of stoppers used for empty evacuated containers, and will not have containers available until the transition is complete.
- Baxter has empty evacuated containers on shortage due to supply constraints.
- B. Braun has evacuated glass containers on shortage due to increased demand for the product and raw material constraints

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=983>

Source link: <http://www.ashp.org>

Dexamethasone Sodium Phosphate

June 12, 2014

Reason for the Shortage

- American Regent voluntarily recalled all dexamethasone sodium phosphate due to the presence of particulate matter in the solution and discontinued manufacture of all dexamethasone 4 mg/mL presentations in March, 2011.¹
- American Regent had temporarily suspended distribution of most drug products including dexamethasone in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.
- Fresenius Kabi (formerly APP) states the dexamethasone sodium phosphate shortage was due to supply and demand issues.²
- Baxter could not provide a reason for the shortage. Baxter sold several products to West-Ward in mid-2011.³
- West-Ward had dexamethasone sodium phosphate injection on shortage due to increased demand.⁴
- Pfizer divested all dexamethasone presentation to Mylan Institutional on December 6, 2013.^{4,5}

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=751>

Source link: <http://www.ashp.org>

Clindamycin Injection

June 12, 2014

Reason for the Shortage

- Pfizer states the Cleocin Add-Vantage vials are on shortage due to manufacturing delays.
- Hospira has clindamycin injection on shortage due to manufacturing delays.
- Akorn launched clindamycin injection in June 2013.
- Sandoz had clindamycin injection on shortage due to increased demand.
- Sagent has clindamycin injection on shortage due to manufacturing delays.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1029>

Source link: <http://www.ashp.org>

Bupropion Hydrochloride 24 hour ER Tablets

June 12, 2014

Reason for the Shortage

- Global and Par state the reason for the shortage is increased demand for product.
- Mylan cannot provide a reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1106>

Source link: <http://www.ashp.org>

Atorvastatin Tablets

June 02, 2014

Reason for the Shortage

- In November 2012, Ranbaxy voluntarily recalled 41 lots of atorvastatin tablets due to possible contamination with very small glass particles. Ranbaxy resumed supply of atorvastatin tablets in late-March 2013.
- Ranbaxy has atorvastatin on shortage due to manufacturing delay.
- Apotex and Mylan Institutional could not provide a reason for the shortage.
- Watson discontinued all atorvastatin presentations in February 2013.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=989>

Source link: <http://www.ashp.org>

Amiodarone Hydrochloride Injection

June 12, 2014

Reason for the Shortage

- Hospira has amiodarone injection on shortage due to manufacturing delays.
- Fresenius Kabi has amiodarone injection on shortage due to increased demand.
- West-Ward stated the reason for the shortage is demand exceeding supply due to current market conditions

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=358>

Source link: <http://www.ashp.org>

Ondansetron Injection

June 13, 2014

Reason for the Shortage

- Caraco temporarily discontinued ondansetron injection.
- West-Ward acquired Baxter's ondansetron vials for injection. West-Ward discontinued ondansetron 2 mg/mL vials in packages of 5 in Spring, 2012.
- BD launched ondansetron 2 mg/mL prefilled syringes in September 2013.

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Hospira has ondansetron on shortage due to manufacturing delays.
- Mylan Institutional acquired ondansetron injection from Pfizer on December 7, 2013. Mylan Institutional temporarily discontinued ondansetron 2 mg/mL injectable products in February 2014.
- Teva is temporarily discontinuing ondansetron 20 mL injection. The company does not have plans to manufacture additional product after the short-dated product is depleted.
- West-Ward had ondansetron on back order due to increased demand.
- Wockhardt has ondansetron injection on shortage due to an FDA import alert.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1040>

Source link: <http://www.ashp.org>

Cefazolin Injection

June 13, 2014

Reason for the Shortage

- Fresenius Kabi, BBraun, West-Ward, and WG Critical Care have cefazolin on shortage due to increased demand.
- Apotex and Sandoz have cefazolin on shortage due to manufacturing delays.
- Hospira has cefazolin on shortage due to manufacturing delays and increased demand.
- Sagent has cefazolin on shortage due to increased demand and shipping delays.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=987>

Source link: <http://www.ashp.org>

Trace Elements Injection

June 16, 2014

Reason for the Shortage

- American Regent has trace element injection on back order due to manufacturing delays.
- American Regent is the sole supplier of FDA-approved combined trace elements.
- In cooperation with FDA, Fresenius Kabi USA is providing Addamel N (adult trace element injection) and Peditrace (pediatric trace element injection) to the US market to help alleviate the shortage. Addamel N

and Peditrace are manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG, the parent company of Fresenius Kabi, USA

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=785>

Source link: <http://www.ashp.org>

Sulfamethoxazole and Trimethoprim Oral Suspension

June 16, 2014

Reason for the Shortage

- Aurobindo could not provide a reason for the shortage.
- Hi-Tech Pharmacal discontinued all presentations of sulfamethoxazole and trimethoprim oral suspension in June 2014.
- Pharmaceutical Associated discontinued sulfamethoxazole and trimethoprim oral suspension in September 2013.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1109>

Source link: <http://www.ashp.org>

Phytonadione (Vitamin K) Injection

June 16, 2014

Reason for the Shortage

- Hospira has vitamin K injection on shortage due to increased demand for the product.
- Oral vitamin K is not affected by this shortage.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=852>

Source link: <http://www.ashp.org>

Paclitaxel Injection

June 16, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) had paclitaxel on shortage due to increase demand for the product.¹
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has

already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.^{2,3}

- Teva has paclitaxel on shortage due to manufacturing delays.⁴
- Sandoz has paclitaxel on back order due to a raw material shortage.⁵
- Hospira has paclitaxel on shortage due to increased demand.^{6,7}
- Sagent has paclitaxel on shortage due to increased demand.⁸
- Pfizer launched paclitaxel 100 mg and 300 mg vials in March, 2012 and launched the 30 mg vials in April, 2012.⁹
- Mylan Institutional acquired paclitaxel injection from Pfizer on December 7, 2013.^{9,10}

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=790>

Source link: <http://www.ashp.org>

Granisetron Hydrochloride Injection

June 16, 2014

Reason for the Shortage

- Akorn discontinued granisetron 0.1 mg/mL 1 mL vials in August, 2011.
- Apotex and Baxter discontinued their granisetron hydrochloride presentations.
- Fresenius Kabi states the shortage was due to manufacturing delays.
- Bedford discontinued granisetron in May, 2011 to concentrate on the manufacturing of other products.
- Roche discontinued Kytril 0.1 mg/mL and 1 mg/mL 1 mL vials in October, 2009. They discontinued the 1 mg/mL 4 mL vials in July 2010.
- Teva states the shortage is due to manufacturing delays.
- Wockhardt discontinued granisetron hydrochloride injection 0.1 mg/mL 1 mL vials in early, 2010.
- FDA imposed an import ban in mid-2013 on several Wockhardt products including granisetron 1 mg/mL 1 mL and 4 mL vials.
- Sagent had granisetron on shortage due to increased demand.
- Sandoz had granisetron on shortage due to increased demand

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=633>

Source link: <http://www.ashp.org>

Fluconazole Injection

June 16, 2014

Reason for the Shortage

- Teva has fluconazole injection on shortage due to manufacturing delays.
- Pfizer had fluconazole injection on shortage due to manufacturing delays related to labeling changes.
- West-Ward has fluconazole injection on shortage due to manufacturing delays.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=644>

Source link: <http://www.ashp.org>

Dimercaprol Injection

June 16, 2014

Reason for the Shortage

- Akorn could not provide a reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1086>

Source link: <http://www.ashp.org>

Cisatracurium Injection

June 16, 2014

Reason for the Shortage

- Sandoz could not provide a reason for the shortage.¹
- Nimbex injection is on shortage due to increased demand

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1072>

Source link: <http://www.ashp.org>

Chorionic Gonadotropin (Human) Injection

June 16, 2014

Reason for the Shortage

- Merck (formerly Schering-Plough) states their product is on allocation to prevent use in the gray market.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=382>

Source link: <http://www.ashp.org>

Calcium Acetate Capsules

June 16, 2014

Reason for the Shortage

- Fresenius Medical cannot provide a reason for the shortage.
- Hawthorne states the reason for the shortage was manufacturing delay.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1002>

Source link: <http://www.ashp.org>

Atropine Sulfate Injection

June 16, 2014

Reason for the Shortage

- American Regent had temporarily suspended manufacture of most drug products in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.
- Hospira states the shortage is due to manufacturing delays.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=814>

Source link: <http://www.ashp.org>

Ampicillin Sulbactam

June 16, 2014

Reason for the Shortage

- AuroMedics Pharma launched new product in mid-June, 2012.
- Hospira states that ampicillin sulbactam vials are on back order due to manufacturing delay.
- Mylan Institutional discontinued ampicillin sulbactam injection in late 2013.
- Sagent has ampicillin sulbactam vials on allocation due to increased demand for the product.
- Pfizer and Sandoz cannot provide a reason for the shortage.
- WG Critical Care launched ampicillin sulbactam 1.5 gram vials in March 2014.

- West-Ward acquired several Baxter products in early 2011.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=805>

Source link: <http://www.ashp.org>

Ceftriaxone Sodium Injection

June 17, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Fresenius Kabi states the reason for the shortage is increased demand.
- Hospira states the reason for the shortage is manufacturing delay.
- Sandoz cannot provide a reason for the shortage.
- WG Critical Care states the reason for the shortage is increased demand

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1101>

Source link: <http://www.ashp.org>

Tranexamic Acid Injection

June 19, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) has tranexamic acid injection on shortage due to increased demand for the product.
- X-Gen had tranexamic acid on shortage due to increased demand

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1049>

Source link: <http://www.ashp.org>

Sodium Chloride 0.9% Injection Bags

June 19, 2014

Reason for the Shortage

- Baxter has 0.9% sodium chloride on shortage due to increased demand.
- Braun had 0.9% sodium chloride on allocation due to increased demand.
- Hospira cites increased demand as the reason for the shortage.
- In cooperation with the FDA, Fresenius Kabi is providing 0.9% sodium chloride to the US market to help alleviate the national shortage. This 0.9% sodium chloride is manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG. There will be presentations available with Australian/English label and the package insert is the same for all imported presentations.^{4,5}
- In cooperation with the FDA, Baxter is providing imported 0.9% sodium chloride to the US market to help alleviate the national shortage. This 0.9% sodium chloride in Viaflo containers is manufactured in Spain by Baxter.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=993>

Source link: <http://www.ashp.org>

Phenylephrine Hydrochloride Injection

June 19, 2014

Reason for the Shortage

- American Regent has phenylephrine injection on shortage due to increased demand for the product.
- Sandoz could not provide a reason for the phenylephrine injection shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=184>

Source link: <http://www.ashp.org>

Olanzapine Injection

June 19, 2014

Reason for the Shortage

- American Regent states the reason for the shortage is manufacturing delay.
- Sandoz stated the reason for the shortage was increased demand

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1093>

Source link: <http://www.ashp.org>

Octreotide Injection

June 19, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) reports that the shortage is due to increased demand for the product.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Sandoz discontinued octreotide injection in 2nd quarter 2013.
- Sagent has octreotide on shortage due to increased demand for the product.
- Teva has octreotide on shortage due to manufacturing delays.
- Wockhardt has octreotide on back order due to an import ban.
- Sandostatin LAR presentations from Novartis are not affected by this shortage

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=803>

Source link: <http://www.ashp.org>

Mirtazapine Tablets

June 19, 2014

Reason for the Shortage

- Actavis (Watson) cannot provide a reason for the shortage.
- Actavis discontinued their mirtazapine 15 mg oral disintegrating tablets in May 2014.
- Greenstone discontinued all remaining mirtazapine presentations in December 2013.
- Sandoz discontinued their mirtazapine presentations in early-2014.
- Teva discontinued various unit dose presentations throughout 2013, including mirtazapine. Teva could not provide a reason for the shortage.

Article link:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1066>

Source link: <http://www.ashp.org>

Methylprednisolone Acetate Injection

June 19, 2014

Reason for the Shortage

- Sandoz and Teva could not provide a reason for the shortage.
- Pfizer had Depo-Medrol injection on shortage due to manufacturing delay.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=923>

Source link: <http://www.ashp.org>

Methotrexate Injection

June 19, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that have already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.²
- Sandoz recalled two lots of methotrexate 40 mL preservative-free vials in May 2013 due to discover of particulate matter during routine quality control inspection.⁵
- Mylan Institutional acquired methotrexate injection from Pfizer on December 6, 2013.^{4, 7}
- Mylan Institutional divested three presentations of methotrexate injection to Intas (Accord Healthcare) in April 2014.^{4,9}
- Bioniche was acquired by Mylan Institutional in September, 2011.^{4,6}
- Teva discontinued methotrexate 4 mL vials in October 2013 due to business reasons.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=26>

Source link: <http://www.ashp.org>

Ketorolac Tromethamine Injection

June 19, 2014

Reason for the Shortage

- American Regent discontinued all ketorolac injection presentations in 2010.
- Fresenius Kabi (formerly APP) states the shortage was due to manufacturing delays.
- Baxter could not provide a reason for the shortage.

- Cura filed for bankruptcy in 2010.
- Hospira has ketorolac on shortage due to manufacturing delays for quality improvement activities and increased demand for the product.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure. West-Ward has ketorolac injection on shortage due to manufacturing delays.
- West-Ward has ketorolac injection on shortage due to manufacturing delays.
- FDA imposed an import ban in mid-2013 on several Wockhardt products including ketorolac.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=593>

Source link: <http://www.ashp.org>

Glycopyrrolate Injection

June 19, 2014

Reason for the Shortage

- American Regent had temporarily suspended manufacture of most drug products in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.
- West-Ward could not provide a reason for the shortage.

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=385>

Source link: <http://www.ashp.org>

Fluorouracil Injection

June 19, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) states fluorouracil is on allocation to prevent excessive purchases.
- Teva has fluorouracil on back order due to manufacturing issues.
- Mylan Institutional temporarily discontinued their fluorouracil injection in May 2013
- Mylan Institutional acquired fluorouracil injection from Pfizer on December 6, 201

Article link: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=798>

Source link: <http://www.ashp.org>

Famotidine Injection

June 19, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.¹
- West-Ward states the shortage is due to manufacturing delays.²
- Oral famotidine products are not affected by this shortage.
- Pfizer launched famotidine injections in March, 2012.³
- Mylan Institutional acquired famotidine injections from Pfizer on December 6, 2013

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=810>

Source link: <http://www.ashp.org>

Ethiodized Oil

June 19, 2014

Reason for the Shortage

- Savage / Nycomed no longer manufactures Ethiodol solution for injection due to a marketing decision.¹
- In cooperation with FDA, Guerbet was importing Lipiodol Ultra-Fluide.^{2,3}
- Guerbet received FDA approval of Lipiodol in April 2014.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=618>

Source link: <http://www.ashp.org>

Doxorubicin Injection

June 19, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.¹

- Pfizer had doxorubicin solution for injection on shortage due to shipping delays.⁵
- Sagent introduced doxorubicin injection in November 2013.⁶
- Mylan Institutional acquired doxorubicin lyophilized powder from Pfizer on December 6, 2013.⁷
- Teva could not provide a reason for the shortage

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=464>

Source link: <http://www.ashp.org>

Dobutamine Injection

June 19, 2014

Reason for the Shortage

- Baxter had dobutamine on back order due to increased demand and manufacturing constraints.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Hospira has dobutamine on shortage due increased demand for the product

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=929>

Source link: <http://www.ashp.org>

Diltiazem Injection

June 19, 2014

Reason for the Shortage

- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in 2014. Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- Hospira states the reasons for the shortage are manufacturing delays and increases in demand.
- West-Ward has diltiazem injection on shortage due to manufacturing delays caused by increased demand due to current market conditions.
- Akorn states the reason for the shortage is increased demand due to market conditions.
- Teva discontinued all diltiazem presentations in March, 2011.
- Biovail discontinued Cardizem Lyo-Ject in 2007 due to business reasons

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=217>
Source link: <http://www.ashp.org>

Cyanocobalamin Injection

June 19, 2014

Reason for the Shortage

- American Regent had temporarily suspended manufacture of most drug products including cyanocobalamin injection in April, 2011.
- American Regent resumed manufacturing in Shirley, New York in early-May, 2011.
- Fresenius Kabi (formerly APP) has cyanocobalamin injection on shortage due to increased demand for the product.

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=947>
Source link: <http://www.ashp.org>

Bupivacaine Injection

June 19, 2014

Reason for the Shortage

- Fresenius Kabi (formerly APP) has Sensorcaine on shortage due to increased demand for the product.
- Hospira has Marcaine and bupivacaine on shortage due to manufacturing delays.
- AuroMedics introduced bupivacaine injection in February 2014

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=864>
Source link: <http://www.ashp.org>

Heparin Sodium Injection

June 19, 2014

Reason for the Shortage

- FDA has issued import bans against 22 Chinese manufacturers of heparin due to inadequate good manufacturing practices (GMPs).¹
- West-Ward obtained five presentations of the heparin sodium injection from Baxter in September, 2011. Baxter only retained two large volume heparin presentations. All other Baxter presentations have been discontinued.^{2,3}

- Fresenius Kabi (formerly APP) reports that heparin products are on back order due to increased demand for the product.⁴
- Hospira states the shortage of heparin vials is due to manufacturing delays.⁵
- Covidien and B. Braun could not provide a reason for the shortage

Article link:<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=387>

Source link: <http://www.ashp.org>

NEW DRUGS COMING TO MARKET

PRODUCT	MFR	ROUTE	INDICATION	PHARMACOLOGY	MARKET RELEASE
Abacavir/ Dolutegravir/ lamivudine	ViiV Healthcare	PO	HIV	Single tab combining integrase inhibitor, replication inhibitor, nucleoside reverse transcriptase inhibitor	NDA filed 10/22/13. FDA action date 10/14.
Asunaprevir	Bristol- Myers Squibb	PO	Hepatitis C	NS3 protease inhibitor	NDA filed 4/14; triple therapy designation (with daclatasvir & BMS 791325) for chronic Hepatitis C.
Belinostat	Spectrum	Inj (IV)	Peripheral T-cell lymphoma	Inhibitor of class I and class II histone deacetylase (HDAC) enzymes, which promote growth of tumor cells	NDA submitted 12/13. FDA priority review. FDA action date 8/9/14.
Ceftolozane/ Tazobactam	Cubist	Inj (IV)	Complicated Urinary Tract Infections (cUTI) and Complicated Intra- Abdominal Infections (cIAI)	Cephalosporin/be ta-lactase inhibitor combination	NDA filed 4/23/14. FDA fast-track and QIDP designation, priority review.
Daclatasvir	Bristol- Myers Squibb	PO	Hepatitis C	NS5A protein inhibitor	NDA filed 4/14; triple therapy

PRODUCT	MFR	ROUTE	INDICATION	PHARMACOLOGY	MARKET RELEASE
					break-through therapy designation (with asunaprevir & BMS 791325) for chronic Hepatitis C.
Elvitegravir	Gilead	PO	HIV	Integrase inhibitor	NDA filed 6/12. FDA complete response letter 4/27/13. NDA re-submitted 4/14. FDA action date 10/4/14.
Faldaprevir	Boehringer Ingelheim	PO	Hepatitis C	Inhibitor of the NS3/4A serine protease	NDA filed 3/6/14; FDA fast track status.
Idelalisib (GS-1101)	Gilead	PO	Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL)	Phosphoinositide-3-kinase (PI3K) inhibitor	NDA for NHL filed 9/11/13 and CLL on 12/6/13. FDA action date 6/8/14 for CLL and 9/11/14 for NHL. FDA break-through therapy designation for relapsed CLL.
Lambrolizumab	Merck	Inj (IV)	Melanoma, NSCLC	Specifically targets	FDA break-

PRODUCT	MFR	ROUTE	INDICATION	PHARMACOLOGY	MARKET RELEASE
ab (MK-3475)				the “programmed death” 1 (PD-1) receptor	through therapy designation 4/13. Rolling BLA submitted 1/14. FDA action date 10/28/14.
Ledipasvir/sofosbuvir	Gilead	PO	Hepatitis C	Fixed dose combination of NS5A protein inhibitor, nucleotide NS5B inhibitor	NDA filed 2/14; Break-through therapy designation granted 8/13; priority review; FDA action date 10/10/2014.
Naloxegol	Nectar/AstraZeneca	PO	Opioid-induced constipation	PEGylated tablet formulation of naloxol (an analogue of naloxone)	NDA filed 9/13. FDA action date 9/14/14.
Oritavancin	The Medicines Company	Inj (IV)	Gram positive infections	Lipoglycopeptide that inhibits cell wall synthesis	Qualified Infectious Disease Product (QIDP) designation 11/13; NDA filed 2/14; FDA action date 8/6/14 with priority review.
Peramivir	BioCryst	Inj (IV)	Influenza	Cyclosporine compound that selectively inhibits the influenza A and B	NDA filed 12/13. FDA action date 12/23/14.

PRODUCT	MFR	ROUTE	INDICATION	PHARMACOLOGY	MARKET RELEASE
				neuraminidase enzyme	
Reconest	Saliz	Inj (IV)	Hereditary angioedema	Complement C1r inhibitor-the major inhibitor of activated Hageman factor, plasmin and kallikrein of the coagulation pathway	BLA filed 4/13. FDA action date delayed until 7/16/14.